var title_f27_55_28528="Superior sulcus PA";
var content_f27_55_28528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superior sulcus tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with superior sulcus tumor at the right apex. Chest radiograph shows a right upper lobe nodule with adjacent apical cap.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28528=[""].join("\n");
var outline_f27_55_28528=null;
var title_f27_55_28529="Patient data flow sheet";
var content_f27_55_28529=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Patient data flow sheet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 766px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A: Alert; D: Drowsy; S: Stuporous; C: Comatose.",
"     <br>",
"      &bull; D: Deep; S: Shallow; N: Normal.",
"      <br>",
"       &Delta; [2 x Na (meq/L)] + [glucose (mg/dL) &divide; 18].",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28529=[""].join("\n");
var outline_f27_55_28529=null;
var title_f27_55_28530="Transverse colon endoscopy";
var content_f27_55_28530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transverse colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse colon seen during colonoscopy. The triangular shape seen here is characteristic of the transverse colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28530=[""].join("\n");
var outline_f27_55_28530=null;
var title_f27_55_28531="Alclometasone: Pediatric drug information";
var content_f27_55_28531=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alclometasone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?19/15/19700?source=see_link\">",
"    see \"Alclometasone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/51/38707?source=see_link\">",
"    see \"Alclometasone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aclovate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F996428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F996446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/15/19700?source=see_link\">",
"      see \"Alclometasone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Children and Adults: Apply to affected area 2-3 times/day. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary. Not recommended for use &gt;3 weeks in children. Occlusive dressings may be used when treating refractory lesions of psoriasis and other deep-seated dermatoses such as localized neurodermatitis (lichen simplex chronicus)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as dipropionate: 0.05% (15 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aclovate&reg;: 0.05% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as dipropionate: 0.05% (15 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aclovate&reg;: 0.05% (15 g [DSC], 60 g [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F996450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply sparingly in a thin film; rub in lightly; for external use only; avoid contact with the eyes. Do not use on open wounds or weeping lesions. Apply sparingly to occlusive dressings.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F996444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store between 2&deg;C and 30&deg;C (36&deg;F and 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F996429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of inflammation of corticosteroid-responsive dermatosis (mild to moderate potency topical corticosteroid)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aclovate&reg; may be confused with Accolate&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cloderm: Brand name for alclometasone [Indonesia], but also brand name for clobetasol [China, India, Malaysia, Singapore, Thailand]; clocortolone [U.S., Canada]; clotrimazole [Germany]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F131079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic:  Acne, allergic dermatitis, hypopigmentation, perioral dermatitis, skin atrophy, striae, miliaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: HPA axis suppression, Cushing's syndrome, growth retardation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, erythema, itching, irritation, dryness, folliculitis, papular rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F996432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alclometasone or any component; viral, fungal, or tubercular skin lesions; herpes (including varicella)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4288931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy have not been established in children &lt;1 year of age; not for use in treatment of diaper dermatitis; generally not for routine use on the face, underarms, or groin areas",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F996433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants and small children, due to larger surface area to body weight ratio and particularly if applying to &gt;20% of body surface area, may be more susceptible to adrenal axis suppression from topical corticosteroid therapy; systemic effects may occur when used on large areas of the body, denuded areas, for prolonged periods of time, or with an occlusive dressing. Hypothalamic pituitary adrenal (HPA) axis suppression may occur; acute adrenal insufficiency may occur with abrupt withdrawal after long term use or with stress; withdrawal or discontinuation should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4804818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some corticosteroids were found to be teratogenic following topical application in animal reproduction studies. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4288934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical signs and symptoms of improvement in condition; assessment of HPA suppression if treatment for prolonged periods",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F996445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Possesses anti-inflammatory, antiproliferative, and immunosuppressive properties",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4288932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Initial response:",
"    </p>",
"    <p style=\"text-indent:2em;\">",
"     Eczema: 5.3 days",
"    </p>",
"    <p style=\"text-indent:2em;\">",
"     Psoriasis: 6.7 days",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Peak response:",
"    </p>",
"    <p style=\"text-indent:2em;\">",
"     Eczema: 13.9 days",
"    </p>",
"    <p style=\"text-indent:2em;\">",
"     Psoriasis: 14.8 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4288933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Topical: 3% (when left on intact skin without an occlusive dressing for 8 hours); large variation in absorption depending upon anatomical sites: Forearm 1%; scalp 4%; scrotum 36%",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Metabolism: Liver, extensive",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F996452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/51/38707?source=see_link\">",
"      see \"Alclometasone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before applying, gently wash area to reduce risk of infection. Apply a thin film to cleansed area and rub in gently and thoroughly until medication vanishes. Do not use for longer than directed; notify physician if condition being treated persists or worsens.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12988 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28531=[""].join("\n");
var outline_f27_55_28531=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131062\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996428\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996446\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131054\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131040\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996450\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996444\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996429\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131081\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131079\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996432\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288931\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996433\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298696\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131049\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131051\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4804818\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288934\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996445\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288932\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288933\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996452\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12988\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12988|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/15/19700?source=related_link\">",
"      Alclometasone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/51/38707?source=related_link\">",
"      Alclometasone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_55_28532="Secobarbital: Patient drug information";
var content_f27_55_28532=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Secobarbital: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/27/32182?source=see_link\">",
"     see \"Secobarbital: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/13/21718?source=see_link\">",
"     see \"Secobarbital: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Seconal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702909",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to secobarbital or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the airway, liver disease, porphyria, or shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696091",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug only for short periods of time (7 to 10 days).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis. Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11911 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-A67B6C3D87-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28532=[""].join("\n");
var outline_f27_55_28532=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220193\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013166\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013165\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013170\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013171\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013173\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013168\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013169\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013174\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013175\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/27/32182?source=related_link\">",
"      Secobarbital: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/13/21718?source=related_link\">",
"      Secobarbital: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_55_28533="Levobunolol: Drug information";
var content_f27_55_28533=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levobunolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/30/30180?source=see_link\">",
"    see \"Levobunolol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/63/2036?source=see_link\">",
"    see \"Levobunolol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betagan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Levobunolol&reg;;",
"     </li>",
"     <li>",
"      Betagan&reg;;",
"     </li>",
"     <li>",
"      Novo-Levobunolol;",
"     </li>",
"     <li>",
"      PMS-Levobunolol;",
"     </li>",
"     <li>",
"      Ratio-Levobunolol;",
"     </li>",
"     <li>",
"      Sandoz-Levobunolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F187741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Nonselective;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F187712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Glaucoma (open-angle, chronic), intraocular hypertension:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     0.25% solution: Instill 1-2 drops into affected eye(s) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     0.5% solution: Instill 1-2 drops into affected eye(s) once daily; may increase to 1 drop twice daily in patients with severe or uncontrolled glaucoma; Maximum dose: Doses &gt;1 drop twice daily (0.5%) are generally not more effective.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F187713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F187695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 0.25% (5 mL, 10 mL); 0.5% (5 mL, 10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betagan&reg;: 0.25% (5 mL [DSC], 10 mL [DSC]); 0.5% (2 mL [DSC], 5 mL, 10 mL, 15 mL) [contains benzalkonium chloride, sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F187680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16225130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only. Wash hands before and after use. Apply gentle pressure to lacrimal sac for 1 minute following instillation. Some solutions contain benzalkonium chloride; remove contact lens prior to administration. Do not touch tip of applicator to eye or other surfaces.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F187696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To lower intraocular pressure in chronic open-angle glaucoma or ocular hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F187745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levobunolol may be confused with levocabastine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Betagan&reg; may be confused with Betadine&reg;, Betoptic&reg; S",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F187739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, cardiac arrest cerebral ischemia, cerebrovascular accident, chest pain, congestive heart failure, heart block, hypotension, palpitation, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia (transient), confusion, depression, dizziness, headache, lethargy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema, pruritus, rash, Stevens-Johnson syndrome, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia masked",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myasthenia gravis exacerbation, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Stinging/burning (up to 33%), blepharoconjunctivitis (5%), blepharoptosis, conjunctivitis, corneal sensitivity decreased, diplopia, iridocyclitis, keratitis, ptosis, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, nasal congestion, respiratory failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F187700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levobunolol or any component of the formulation; bronchial asthma, severe COPD, sinus bradycardia, second- or third-degree AV block, overt cardiac failure, cardiogenic shock",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F187684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular insufficiency: Due to a possible effect on blood pressure and pulse, use with caution in patients with cerebrovascular insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated HF and monitor for a worsening HF (diminished myocardial contractility may lead to more severe failure); patients without a history of HF should discontinue use with the first symptoms of heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD): Use with caution in patients with PVD (including Raynaud's).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt beta-adrenergic blocker withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Beta-blockers: Concomitant use with other topical beta-blockers should generally be avoided; monitor for increased effects (systemic or intraocular) with concomitant use of a systemic beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly with other disease states or syndromes that may be affected by a beta-blocker (CHF, COPD, etc); systemic absorption may occur with ophthalmic administration; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metabisulfite: Ophthalmic solutions contain metabisulfite, which may cause allergic reactions in some individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Systemic absorption of levobunolol and adverse effects may occur with ophthalmic use, including respiratory and cardiovascular effects (including bradycardia and/or hypotension). Beta-blocker therapy should not be withdrawn abruptly in order to avoid acute tachycardia, hypertension, and/or ischemia. Patients undergoing major surgery should be gradually tapered off therapy prior to procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should not be used alone in angle-closure glaucoma (has no effect on pupillary constriction).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F187689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F187690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9951563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. If ophthalmic agents are needed for the treatment of glaucoma during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Johnson,2001; Samples, 1988)",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9953844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16225126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if levobunolol is excreted in breast milk; however, systemic beta-blockers and topical timolol are excreted in breast milk. The manufacturer recommends that caution be exercised when administering levobunolol to nursing women. The minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the nursing infant (Johnson, 2001; Samples, 1988).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F187702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Betagan Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (10 mL): $93.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Levobunolol HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (5 mL): $14.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (10 mL): $47.01",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F187693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure, heart rate, funduscopic exam, visual field testing",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F187703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Betagan (AE, AR, AU, BE, BH, BR, CL, CN, CY, DK, EG, ES, FR, GB, HK, IE, IL, IN, IQ, IR, JO, KP, KW, LB, LU, LY, MX, MY, NL, NZ, OM, PT, QA, SA, SG, SY, TH, TR, UY, YE, ZA);",
"     </li>",
"     <li>",
"      Bunolgan (TW);",
"     </li>",
"     <li>",
"      Levosan (PK);",
"     </li>",
"     <li>",
"      Orbunol (PE);",
"     </li>",
"     <li>",
"      Vistagan (AT, CH, CO, CZ, DE, GR, HN, HR, HU, IT, PL, RU, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F187683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A nonselective beta-adrenergic blocking agent that lowers intraocular pressure by reducing aqueous humor production and possibly increases the outflow of aqueous humor",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F187699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Up to 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Johnson SM, Martinez M, and Freedman S, \"Management of Glaucoma in Pregnancy and Lactation,\"",
"      <i>",
"       Surv Ophthalmol",
"      </i>",
"      , 2001, 45(5):449-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/55/28533/abstract-text/11274697/pubmed\" id=\"11274697\" target=\"_blank\">",
"        11274697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/55/28533/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Samples JR and Meyer SM, &ldquo;Use of Ophthalmic Medications in Pregnant and Nursing Women,&rdquo;",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 1988, 106(5):616-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/55/28533/abstract-text/2903673/pubmed\" id=\"2903673\" target=\"_blank\">",
"        2903673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9552 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28533=[""].join("\n");
var outline_f27_55_28533=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187708\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187709\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187741\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187712\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187713\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160293\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160294\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187695\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187680\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225130\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187696\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187745\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187739\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187700\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187684\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299587\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187689\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187690\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9951563\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9953844\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225126\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187702\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187693\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187703\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187683\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187699\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9552\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9552|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/30/30180?source=related_link\">",
"      Levobunolol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/63/2036?source=related_link\">",
"      Levobunolol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_55_28534="Bacterial tracheitis in children: Treatment and prevention";
var content_f27_55_28534=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bacterial tracheitis in children: Treatment and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28534/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28534/contributors\">",
"     Charles R Woods, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28534/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28534/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28534/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28534/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28534/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/55/28534/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment and prevention of bacterial tracheitis in children will be reviewed here. The clinical features and diagnosis of bacterial tracheitis and tracheal infections associated with tracheostomy tubes and endotracheal intubation in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=see_link\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2932?source=see_link\">",
"     \"Tracheal infections associated with tracheostomy tubes and endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial tracheitis is an invasive exudative bacterial infection of the soft tissues of the trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/1\">",
"     1",
"    </a>",
"    ]. Other terms that have been used to describe this condition include \"bacterial croup\", \"membranous croup\", \"pseudomembranous croup\", \"acute laryngotracheobronchitis\", and \"membranous laryngotracheobronchitis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=see_link&amp;anchor=H2#H2\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstones of treatment for bacterial tracheitis are maintenance of the airway, fluid resuscitation (if needed), and administration of appropriate antimicrobial agents. Some children require emergent or urgent evaluation of the airway via endoscopy. This procedure generally is best performed in the operating room, intensive care unit, or equivalent setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=see_link&amp;anchor=H18#H18\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\", section on 'Endoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with bacterial tracheitis generally should be admitted to a pediatric intensive care unit even if endotracheal intubation is not required, so they can be monitored for potential disease progression. Successful management without admission to an intensive care unit has been described in a minority of patients (approximately 10 percent in a large case series) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     AIRWAY MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of the airway is the mainstay of treatment of bacterial tracheitis. Initial airway management is based upon the degree of respiratory distress as determined by clinical assessment. In patients with signs of total or near-total airway obstruction, airway control precedes diagnostic evaluation.",
"   </p>",
"   <p>",
"    Patients with suspected bacterial tracheitis and signs of severe upper airway obstruction should be transported to the operating room, if time allows, where an artificial airway can be established, surgically if necessary. A physician skilled at airway management should monitor the patient at all times. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link&amp;anchor=H22#H22\">",
"     \"The difficult pediatric airway\", section on 'Surgical airway'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental humidified oxygen should be provided for children with respiratory distress or hypoxia as measured by pulse oximetry or arterial blood gas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy (flexible or rigid) is an important diagnostic and therapeutic component in the management of children with bacterial tracheitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Endoscopic findings can confirm the diagnosis, and the procedure may be necessary to remove adherent or copious pseudomembranous exudates, which can cause airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/4\">",
"     4",
"    </a>",
"    ]. Endoscopic debridement of tracheal exudates may produce sufficient improvement to permit further management without intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some children may require serial endoscopic debridement for ongoing secretions that cause endotracheal tube plugging or recurrent episodes of respiratory distress in children not initially intubated, but this generally is unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether every child with suspected bacterial tracheitis requires endoscopy is uncertain. Routine endoscopy was performed in some case series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]; in others, a subset of children was managed without endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/6\">",
"     6",
"    </a>",
"    ]. Children who require intubation based upon the severity of their clinical presentation or have progression of respiratory distress are those most likely to benefit from endoscopy.",
"   </p>",
"   <p>",
"    When endoscopy is needed, we suggest rigid endoscopy for suctioning of tracheal membranes and obtaining specimens for culture in children with high clinical suspension of bacterial tracheitis and moderate to severe respiratory distress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impending airway compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/4\">",
"     4",
"    </a>",
"    ]. For children with less severe presentations, flexible endoscopy is an alternative.",
"   </p>",
"   <p>",
"    Children with only minor tracheal irregularities on plain radiographs, absence of respiratory distress and hypoxia, and no other clinical indications for intubation may be initially managed without endoscopy. Such children should be closely monitored for respiratory distress and hypoxia should the disease progress. Copious exudates or detaching pseudomembranes could obstruct the airway, necessitating intubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Artificial airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children with bacterial tracheitis require endotracheal intubation for airway obstruction related to purulent secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/3,6-8\">",
"     3,6-8",
"    </a>",
"    ]. In a systematic review of 300 cases, intubation was performed in approximately 72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/9\">",
"     9",
"    </a>",
"    ]. Tracheostomy usually is not necessary during initial management but may be necessary for residual subglottic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/1,3,6,8\">",
"     1,3,6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are intubated during treatment for bacterial tracheitis require meticulous respiratory nursing care. Frequent suctioning is necessary to prevent obstruction of the endotracheal tube, which can be fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/10\">",
"     10",
"    </a>",
"    ]. Post-intubation care is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H25#H25\">",
"     \"Emergent endotracheal intubation in children\", section on 'Post-intubation care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extubation generally can be accomplished when an air leak develops around the endotracheal tube, and tracheal secretions have become minimal (usually after three to six days of treatment). Serial bronchoscopy to document resolution of local inflammatory signs in the trachea is not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bronchodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no formal studies of bronchodilator therapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    , epinephrine) in the treatment of bacterial tracheitis. Some authors suggest that a lack of response to racemic epinephrine is helpful in distinguishing bacterial tracheitis from croup [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/4\">",
"     4",
"    </a>",
"    ]. Wheezing associated with tracheitis may or may not improve after bronchodilator therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/10\">",
"     10",
"    </a>",
"    ]. Bronchodilator therapy may help to reduce bronchospasm or subglottic edema or clear tracheal secretions. In addition, bronchodilator therapy may be beneficial in some children with bronchiolitis as the predisposing viral illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=see_link&amp;anchor=H403689989#H403689989\">",
"     \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\", section on 'Other therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A trial of inhaled bronchodilators for children hospitalized with bacterial tracheitis may be warranted, but expected benefit, if any, in the absence of associated wheezing from concurrent viral infection would be related to clearance of tracheal secretions. Repeated administration with lack of clinical response, as in viral bronchiolitis, is unwarranted. Patients should be assessed before and up to one hour after treatment. If no clinical response is seen within one hour of treatment, the therapy should be discontinued. If there is a clinical response, bronchodilator therapy can be administered every four to six hours but should be assessed for ongoing utility after each treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are not part of the routine management of bacterial tracheitis. Empiric use of glucocorticoids is not addressed in most case series. However, in a multicenter retrospective case series, 30 of 34 patients received glucocorticoids, predominantly",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/11\">",
"     11",
"    </a>",
"    ]. The use of glucocorticoids in the initial management does not seem to influence overall outcome. We suggest not using glucocorticoids routinely in the initial management of children with bacterial tracheitis.",
"   </p>",
"   <p>",
"    Glucocorticoids have been used to facilitate extubation in children with bacterial tracheitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/3,12\">",
"     3,12",
"    </a>",
"    ] but may not be routinely required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FLUID MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid management is determined on a case-by-case basis, depending upon blood pressure, perfusion, and clinical signs of hypovolemia. Children with associated septic shock may require vigorous fluid resuscitation and pressor support; less aggressive fluid management may be sufficient in milder cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to airway management, patients with bacterial tracheitis require antimicrobial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antibacterial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antibiotic regimen for bacterial tracheitis is determined on a case-by-case basis. The optimal antibacterial therapy for bacterial tracheitis has not been studied in randomized controlled trials. The initial antibiotic regimen is individualized according to the likely pathogens, local antimicrobial susceptibility, and Gram stain. When culture and susceptibility results are available, the regimen can be tailored as indicated.",
"   </p>",
"   <p>",
"    We suggest that initial therapy for bacterial tracheitis include coverage for the most frequently isolated pathogens. These include",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    (including methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    ), group A streptococcus,",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    , and",
"    <em>",
"     Moraxella catarrhalis",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=see_link&amp;anchor=H5#H5\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Broad coverage for these pathogens generally requires an antistaphylococcal agent (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    )",
"    <strong>",
"     plus",
"    </strong>",
"    a third-generation cephalosporin (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef58913 \" href=\"UTD.htm?24/44/25293\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/11\">",
"     11",
"    </a>",
"    ]. An antistaphylococcal agent",
"    <strong>",
"     plus",
"    </strong>",
"    &nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/3/29750?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    also may be reasonable. When the patient history suggests potential for severe hypersensitivity reaction to beta-lactam antibiotics, vancomycin or clindamycin",
"    <strong>",
"     plus",
"    </strong>",
"    a quinolone antibiotic (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    if",
"    <em>",
"     Pseudomonas",
"    </em>",
"    spp is a concern,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33968?source=see_link\">",
"     levofloxacin",
"    </a>",
"    if",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    is suspected) may be a reasonable alternative.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1430?source=see_link\">",
"     Aztreonam",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    may be substituted for the quinolone if the hypersensitivity reaction was not severe (ie, anaphylaxis). Consultation with an expert in pediatric infectious disease may be warranted.",
"   </p>",
"   <p>",
"    Local antimicrobial susceptibility patterns should guide the choice of agents. Gram stain results, when available from endoscopic evaluations, also may guide empiric therapy. As an example,",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    and gram-negative enteric microbes have been isolated from children in multiple series. If gram-negative rods are seen in Gram stain, empiric coverage may need to be broadened if local susceptibility patterns suggest an increased likelihood of",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    and gram-negative resistance to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    . Agents such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    , or a quinolone may be needed in addition to antistaphylococcal coverage for methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    Gram stain results may suggest a particular pathogen before culture results are available. However, broad-spectrum antimicrobial therapy should be continued until culture results are available, because Gram stain results are subject to observer misinterpretation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum effective duration of antibiotic therapy is unknown. Case series provide little meaningful guidance, but a 10-day course appears to be sufficient. Longer courses may be warranted for children with associated extratracheal sites of infection or persistence of tracheal inflammation beyond 7 to 10 days. Completion of the course with oral antibiotics may be an option depending upon the availability of oral agents effective against the documented or presumed pathogen(s), once recovery is sufficient to permit resumption of oral feedings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy may be warranted when influenza is the predisposing viral etiology, and viral symptoms have been present for less than two or possibly three days in immunocompetent hosts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H37#H37\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical hospital length of stay, intensive care length of stay, and number of days of ventilator support required for children with bacterial tracheitis who require intubation are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef68126 \" href=\"UTD.htm?12/15/12540\">",
"     table 2",
"    </a>",
"    ). Some children require prolonged intensive care, intubation, and hospitalization. In a systematic review of case series with at least 10 patients (total of 217 cases), the mean duration of intubation ranged from 48 to 182 hours, and the mean duration of hospitalization ranged from 5 to 12 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OUTCOMES AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with bacterial tracheitis usually recover without sequelae. The tracheal mucosa heals without scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/6,10\">",
"     6,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Death can occur from primary respiratory failure with cardiac arrest, plugging of the endotracheal tube (in intubated patients), associated toxic shock syndrome, and bronchospasm with associated pneumothorax and pneumomediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/6,7,10\">",
"     6,7,10",
"    </a>",
"    ]. Cerebral anoxia can occur if there is a delay in seeking care or difficulty securing or maintaining the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. The clinical course can be complicated by acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome, or postobstructive pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/9\">",
"     9",
"    </a>",
"    ]. Residual subglottic stenosis has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of 300 cases, the mortality rate was 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/9\">",
"     9",
"    </a>",
"    ]. The frequency of complications was as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28534/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiorespiratory arrest &ndash; 3.3 percent",
"     </li>",
"     <li>",
"      Hypotension &ndash; 2 percent",
"     </li>",
"     <li>",
"      Pulmonary edema &ndash; 1.3 percent",
"     </li>",
"     <li>",
"      Pneumothorax &mdash; 1.3 percent",
"     </li>",
"     <li>",
"      ARDS &ndash; 1 percent",
"     </li>",
"     <li>",
"      Subglottic stenosis &ndash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination against pneumococci and viruses (eg, measles, influenza) that may predispose children to bacterial tracheitis and other secondary bacterial infections of the respiratory tract is the primary means of prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"     \"Standard immunizations for children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial tracheitis is an exudative bacterial infection of the soft tissues of the trachea. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintenance of the airway is the mainstay of treatment. Initial airway management is based upon the degree of respiratory distress as determined by clinical assessment. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopy can be used to confirm the diagnosis and often is necessary to remove adherent or copious pseudomembranous exudates. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with bacterial tracheitis require endotracheal intubation. Tracheotomy usually is necessary for only residual subglottic stenosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Artificial airway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using glucocorticoids in the initial management of children with bacterial tracheitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that empiric antimicrobial therapy for bacterial tracheitis include coverage for",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      (including methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      ), group A streptococcus,",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      ,",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      , and",
"      <em>",
"       Moraxella catarrhalis",
"      </em>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Possible regimens are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef58913 \" href=\"UTD.htm?24/44/25293\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Antibacterial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiviral therapy may be warranted when influenza is the predisposing viral etiology. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antiviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with bacterial tracheitis usually recover without sequelae. The mortality rate is approximately 3 percent. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Outcomes and complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/1\">",
"      Jones R, Santos JI, Overall JC Jr. Bacterial tracheitis. JAMA 1979; 242:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/2\">",
"      Gallagher PG, Myer CM 3rd. An approach to the diagnosis and treatment of membranous laryngotracheobronchitis in infants and children. Pediatr Emerg Care 1991; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/3\">",
"      Salamone FN, Bobbitt DB, Myer CM, et al. Bacterial tracheitis reexamined: is there a less severe manifestation? Otolaryngol Head Neck Surg 2004; 131:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/4\">",
"      Eckel HE, Widemann B, Damm M, Roth B. Airway endoscopy in the diagnosis and treatment of bacterial tracheitis in children. Int J Pediatr Otorhinolaryngol 1993; 27:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/5\">",
"      Graf J, Stein F. Tracheitis in pediatric patients. Semin Pediatr Infect Dis 2006; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/6\">",
"      Hopkins A, Lahiri T, Salerno R, Heath B. Changing epidemiology of life-threatening upper airway infections: the reemergence of bacterial tracheitis. Pediatrics 2006; 118:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/7\">",
"      Liston SL, Gehrz RC, Siegel LG, Tilelli J. Bacterial tracheitis. Am J Dis Child 1983; 137:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/8\">",
"      Huang YL, Peng CC, Chiu NC, et al. Bacterial tracheitis in pediatrics: 12 year experience at a medical center in Taiwan. Pediatr Int 2009; 51:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/9\">",
"      Tebruegge M, Pantazidou A, Yau C, et al. Bacterial tracheitis - tremendously rare, but truly important: A systematic review. J Pediatr Infect Dis 2009; 4:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/10\">",
"      Kasian GF, Bingham WT, Steinberg J, et al. Bacterial tracheitis in children. CMAJ 1989; 140:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/11\">",
"      Tebruegge M, Pantazidou A, Thorburn K, et al. Bacterial tracheitis: a multi-centre perspective. Scand J Infect Dis 2009; 41:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28534/abstract/12\">",
"      Bernstein T, Brilli R, Jacobs B. Is bacterial tracheitis changing? A 14-month experience in a pediatric intensive care unit. Clin Infect Dis 1998; 27:458.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6044 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28534=[""].join("\n");
var outline_f27_55_28534=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      AIRWAY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Artificial airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bronchodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FLUID MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antibacterial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OUTCOMES AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6044\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6044|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/44/25293\" title=\"table 1\">",
"      Bacterial tracheitis Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/15/12540\" title=\"table 2\">",
"      Bacterial tracheitis course",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=related_link\">",
"      Bacterial tracheitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=related_link\">",
"      Bronchiolitis in infants and children: Treatment; outcome; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2932?source=related_link\">",
"      Tracheal infections associated with tracheostomy tubes and endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_55_28535="Cervical ripening and induction of labor in women with a prior cesarean delivery";
var content_f27_55_28535=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical ripening and induction of labor in women with a prior cesarean delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28535/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28535/contributors\">",
"     Deborah A Wing, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28535/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28535/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28535/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28535/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/55/28535/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of failed induction and the possibility of uterine rupture are major concerns of clinicians caring for women undergoing a trial of labor after a previous cesarean delivery (TOLAC; formerly called vaginal birth after a previous cesarean [VBAC]). The best method, efficacy, and safety of cervical ripening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    labor induction in these women has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/1\">",
"     1",
"    </a>",
"    ]. Available evidence is inconclusive because no randomized trials comparing the outcome of induction of labor in women with prior cesareans to elective repeat cesarean delivery (ERCD) have been performed; data are mostly limited to findings from retrospective studies of fair to poor quality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/2\">",
"     2",
"    </a>",
"    ]. These data are insufficient for many reasons, including inconsistent definitions of uterine rupture and dehiscence, wide variation in induction protocols (eg, timing and dosage of prostaglandins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration), heterogeneity in patient populations, and inconsistency in primary outcome measures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical ripening and induction of labor in women attempting TOLAC with a live fetus will be reviewed here. Other issues relating to TOLAC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link\">",
"     \"Choosing the route of delivery after cesarean birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overall risks and benefits of induction in the setting of a prior cesarean delivery are different when the fetus is dead and thus bears no risk from uterine rupture. Management of fetal demise in a woman with a prior cesarean delivery is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/35/1591?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis and management of stillbirth\", section on 'Options for women with a previous cesarean delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIKELIHOOD OF SUCCESSFUL INDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review identified 14 fair-quality studies, and no good-quality studies, on the benefits and risks of inducing labor in patients with prior cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/4\">",
"     4",
"    </a>",
"    ]. Induction was more likely to result in cesarean delivery than spontaneous labor, &nbsp;given that this has been consistently shown in women without a scarred uterus (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    ). The mean vaginal delivery rates for women with a prior cesarean delivery undergoing spontaneous labor and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    induction were 80 percent (range 65 to 89 percent) and 68 percent (range 56 to 82 percent), respectively.",
"   </p>",
"   <p>",
"    Subsequent to this review, a prospective observational study including almost 12,000 women with one prior low-transverse cesarean delivery compared pregnancy outcomes after induced versus spontaneous labor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/5\">",
"     5",
"    </a>",
"    ]. As expected, induction of labor was associated with a significantly higher risk of unsuccessful TOLAC (ie, cesarean delivery) than spontaneous labor, but two factors significantly increased the chance of success: (1) a previous history of vaginal delivery and (2) favorable cervical status (modified Bishop score &ge;6). Successful induction occurred in 91 percent of women with a prior vaginal delivery and a favorable cervix, 77 percent of women with a prior vaginal delivery but an unfavorable cervix, 69 percent of women with no prior vaginal delivery but a favorable cervix, and 45 percent of women with no prior vaginal delivery and an unfavorable cervix.",
"   </p>",
"   <p>",
"    Using multivariable modeling, one group analyzed data from 9616 women to construct a calculator that estimates the likelihood of successful induction in women with a prior cesarean delivery; it is available online at",
"    <span class=\"nowrap\">",
"     file://www.bsc.gwu.edu/mfmu/vagbrth2.html",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK OF UTERINE RUPTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with a prior cesarean delivery, uterine rupture is a concern and induced labor appears to be associated with a higher rate of uterine rupture than spontaneous labor. A systematic review of pooled data from controlled studies of women with prior cesarean delivery reported the odds of uterine rupture with induction versus spontaneous labor was OR 6.15 (95% CI 0.74-51.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/4\">",
"     4",
"    </a>",
"    ]. All but one of the studies had a point estimate indicating increased risk of rupture, but confidence intervals were wide. A large, well-designed prospective study, not included in the pooled estimate, reported an OR 2.86 (95% CI 1.75-4.67); the absolute risks of rupture were 1 percent with induction versus 0.4 percent with spontaneous labor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, several factors affect the risk of rupture in women with prior cesarean deliveries. In a nested case-control study, women induced with a favorable cervix had a similar risk of rupture as women who entered labor spontaneously (HR 1.5, 95% CI 0.97-2.36), whereas an unfavorable cervix increased the risk of rupture (HR 4.09, 95% CI 1.82-9.17) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, women with a prior vaginal delivery were at no increased risk of rupture with induction of labor (HR 0.78, 95% 0.42-1.37).",
"   </p>",
"   <p>",
"    The method of cervical",
"    <span class=\"nowrap\">",
"     ripening/induction",
"    </span>",
"    can affect the outcome: induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    appears to have a lower risk for uterine rupture than prostaglandins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oxytocin induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of retrospectively collected data on women with prior cesarean births did not find that the rate of uterine scar disruption was significantly higher for women who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    for induction of labor compared to women who begin labor spontaneously (pooled OR 2.10, 95% CI 0.76-5.78) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/4\">",
"     4",
"    </a>",
"    ]. These results should be interpreted with caution, given the absence of data from large randomized trials; the paucity of good quality controlled studies; and the observation that most series reported an increased risk of uterine rupture with induction, but with wide confidence intervals so that statistical significance could not be demonstrated. Maximal oxytocin infusion rates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total oxytocin doses administered were rarely reported, thus a dose cut-off above which the risk of uterine rupture increases cannot be ascertained from the existing data. This is important because a dose-response relationship appears to exist between maximum oxytocin dose and uterine rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. At this time, however, there are no high quality data for the optimal maximum dose of oxytocin to be used during labor in women with prior cesarean deliveries. We suggest a judicious approach that adheres to the institution's general policy on use of oxytocin. A low-dose infusion typically consists of an initial dose between 0.5 and 2.0",
"    <span class=\"nowrap\">",
"     mU/mL,",
"    </span>",
"    with incremental increases of 1 to 2",
"    <span class=\"nowrap\">",
"     mU/mL",
"    </span>",
"    at 15- to 40-minute intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest prospective study to evaluate the risk of rupture by labor status in women with one or more cesarean deliveries (n = 17,898 trials of labor and 15,801 ERCDs) was not included in the pooled analysis cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/7\">",
"     7",
"    </a>",
"    ]. In this series, women who underwent induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    alone had a significantly higher risk of uterine rupture than those in spontaneous labor (OR 3.01, 95% CI 1.66-5.46). The actual rate of uterine rupture by category was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ERCD without labor, 0",
"     </li>",
"     <li>",
"      spontaneous labor, 4 per 1000",
"     </li>",
"     <li>",
"      labor induced with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      alone, 11 per 1000",
"     </li>",
"     <li>",
"      labor induced with mechanical dilation with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      , 9 per 1000",
"     </li>",
"     <li>",
"      prostaglandin-induced labor with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      , 14 per 1000",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a secondary analysis, a dose-response relationship between increasing doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    and uterine rupture was identified [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/10\">",
"     10",
"    </a>",
"    ]. Doses exceeding 20",
"    <span class=\"nowrap\">",
"     mU/min",
"    </span>",
"    increased the risk for uterine rupture at least four-fold, and should only be used in cases where the risk-benefit ratio favors their use.",
"   </p>",
"   <p>",
"    These data do not allow a definitive conclusion as to whether use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    for induction of labor in women attempting vaginal birth after a previous cesarean delivery is associated with an increased risk of uterine rupture. Certainly, clinical decision-making as to whether to administer oxytocin to women with prior cesareans is influenced by a number of different factors, including presence or absence of antecedent uterine activity, condition or ripeness of the cervix, gestational age at the time of the induction, past history of vaginal births, and the indication for which the induction is being undertaken. In the absence of definitive data showing a high risk of rupture, oxytocin for induction of labor in TOLAC candidates is an appropriate option when performed for standard obstetrical indications. The American College of Obstetricians and Gynecologists (ACOG) acknowledges that induction of labor may be necessary for women with previous cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/12\">",
"     12",
"    </a>",
"    ]. They advise counseling patients as to the risks and benefits of oxytocin induction in this setting and selecting women most likely to give birth vaginally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link\">",
"     \"Choosing the route of delivery after cesarean birth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link&amp;anchor=H18438373#H18438373\">",
"     \"Choosing the route of delivery after cesarean birth\", section on 'Optimum candidates for TOLAC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the literature does not support the clinical effectiveness of intrauterine pressure catheter monitoring for the prediction of uterine rupture, we have found that knowledge of intrauterine pressure can be useful for judicious titration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28053?source=see_link\">",
"     \"Insertion of intrauterine pressure catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2772734\">",
"    <span class=\"h3\">",
"     Oxytocin for cervical ripening",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data regarding administration of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    for cervical ripening. This approach has the potential for serial induction over several days; delaying delivery for this length of time is generally not advisable for most medical and some obstetrical indications for induction of labor.",
"   </p>",
"   <p>",
"    The combination of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    and a mechanical method of cervical ripening also appears to be ineffective. A trial of 200 women with singleton pregnancies presenting for preinduction ripening randomly assigned them to receive either a Foley catheter alone or a Foley catheter plus low-dose oxytocin (maximum dose 10",
"    <span class=\"nowrap\">",
"     milliunits/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/13\">",
"     13",
"    </a>",
"    ]. Women with a previous cesarean delivery were not excluded. Addition of low dose oxytocin to transcervical Foley catheter cervical ripening did not shorten the time to delivery and had no effect on the likelihood of delivery within 24 hours or vaginal delivery rate. No uterine ruptures occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prostaglandins for cervical ripening/induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , there are no data from large randomized trials and a paucity of data from good quality controlled studies on which to base a recommendation on use of prostaglandins alone or with other agents for cervical",
"    <span class=\"nowrap\">",
"     ripening/induction",
"    </span>",
"    of labor in TOLAC. Most data on use of prostaglandins in women with a prior cesarean delivery were derived from observational studies in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (PGE1) was used. Reports on use of other prostaglandins, such as PGE2, are limited by their small size, the coadministration of oxytocin, and stratification by prior vaginal delivery.",
"   </p>",
"   <p>",
"    Concern regarding the use of prostaglandins arose after publication of a population-based cohort study that analyzed data from 20,095 primiparous women who gave birth to live singleton infants by cesarean and subsequently delivered a second singleton child [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/14\">",
"     14",
"    </a>",
"    ]. The rate of uterine rupture by category was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ERCD without labor, 1.6 per 1000",
"     </li>",
"     <li>",
"      spontaneous labor, 5.2 per 1000",
"     </li>",
"     <li>",
"      labor induced without use of prostaglandins, 7.7 per 1000",
"     </li>",
"     <li>",
"      labor induced with use of prostaglandins, 24.5 per 1000",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is a reasonable assumption that the majority of \"labor induced without use of prostaglandins\" were",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    -only inductions.",
"   </p>",
"   <p>",
"    The rates of uterine rupture in women with spontaneous labor and women in whom labor was \"induced without prostaglandins\" were not significantly different, but both were significantly higher than the rate of uterine rupture for ERCD without labor. The highest risk of uterine rupture occurred in prostaglandin-induced labors. Compared to ERCD, the relative risk of rupture with use of prostaglandins was RR 15.6 (95% CI 8.1-30.0). However, it is important to note that all of the information in this study was derived from a database using hospital discharge coding and birth certificates; no individual chart reviews were performed to verify the uterine ruptures or medications administered. Thus, there is a significant potential for missing and inaccurate data [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings were not confirmed in the large prospective study discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Oxytocin induction'",
"    </a>",
"    above.) In this series, there was no statistically significant difference in the rate of uterine rupture when prostaglandins were used versus other methods of induction. The rate of uterine rupture by category was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ERCD without labor, 0",
"     </li>",
"     <li>",
"      spontaneous labor, 4 per 1000",
"     </li>",
"     <li>",
"      labor induced with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      alone, 11 per 1000",
"     </li>",
"     <li>",
"      labor induced without prostaglandins (mechanical dilation with ot without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      ), 9 per 1000",
"     </li>",
"     <li>",
"      prostaglandin-induced labor with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      , 14 per 1000",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings in these two studies are confounded by heterogeneous approaches to prostaglandin use for cervical ripening and to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration. The increased risk of rupture may be related to characteristics of women who receive prostaglandins rather than the drug itself; as an example, women who receive prostaglandins are much more likely to have an unfavorable cervix than women induced with oxytocin or who enter labor spontaneously. Although some studies describe outcomes for labors induced with oxytocin alone, few describe outcomes for use of prostaglandins alone. In one such study, prostaglandins alone were not associated with uterine rupture, but sequential use of prostaglandin and oxytocin was associated with uterine rupture (OR 3.07, 95% CI 0.98-9.88) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These two studies also did not specify the types of prostaglandin used. A randomized trial on use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    for cervical ripening or labor induction in women with previous cesarean births was stopped early because of safety concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/17\">",
"     17",
"    </a>",
"    ]. This trial and several case reports have led us and others to conclude that misoprostol may be associated with a higher risk of uterine rupture than other prostaglandins and therefore should not be used in women attempting TOLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACOG advises that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (prostaglandin E1)",
"    <strong>",
"     not",
"    </strong>",
"    be used for cervical ripening or labor induction in women in the third trimester with prior uterine incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/12\">",
"     12",
"    </a>",
"    ]. The Society of Obstetricians and Gynaecologists of Canada came to similar conclusions regarding the use of misoprostol, but allowed for use of prostaglandin E2 in rare circumstances and after appropriate counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/21\">",
"     21",
"    </a>",
"    ]. In contrast, the United Kingdom National Institute for Clinical Excellence concluded cautious use of vaginal prostaglandins in women with prior cesareans appears to be safe based on review of observational data and extrapolation of data related to labor induction in women in other subgroups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cervical ripening with mechanical methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on mechanical methods of cervical ripening in this population are limited by small sample size and retrospective analysis, but generally reassuring. Combined results from two studies showed that the rate of rupture in women with previous cesarean delivery undergoing induction with transcervical Foley",
"    <span class=\"nowrap\">",
"     catheter/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"      oxytocin",
"     </a>",
"    </span>",
"    was similar to that in women attempting TOLAC who labored spontaneously (5 ruptures among 384 women [1.3 percent] versus 22 ruptures in 2081 women [1.1 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a retrospective study of 972 TOLACs in 936 women from a single institution observed an increased risk of uterine rupture following a variety of preinduction cervical ripening techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/25\">",
"     25",
"    </a>",
"    ]. The use of a Foley catheter more than tripled the risk of uterine rupture during induction compared to women who entered labor spontaneously (OR 3.67, 95% CI 1.46-9.23). However, none of these women developed the rupture during the process of cervical ripening and they received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    after the catheter was removed.",
"   </p>",
"   <p>",
"    The Society of Obstetricians and Gynaecologists of Canada guidelines on mechanical methods of cervical ripening state &ldquo;a Foley catheter may be safely used to ripen the cervix in a woman planning a trial of labor (TOL) after cesarean delivery&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/21\">",
"     21",
"    </a>",
"    ]. ACOG&rsquo;s position is &ldquo;given the lack of compelling data suggesting increased risk with mechanical dilation and transcervical catheters, such interventions may be an option for TOLAC candidates with an unfavorable cervix&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28535/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of mechanical methods of cervical ripening is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=see_link&amp;anchor=H3#H3\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\", section on 'Mechanical methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/60/20418?source=see_link\">",
"       \"Patient information: Vaginal birth after cesarean delivery (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/33/27155?source=see_link\">",
"       \"Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction of labor in women with prior cesareans is more likely to result in cesarean delivery than if they enter labor spontaneously. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Likelihood of successful induction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Induced labor appears to be associated with a higher rate of uterine rupture than spontaneous labor, but the absolute risk of rupture is low. Inductions in women with a favorable cervix or a previous vaginal delivery are associated with the lowest risk of rupture. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk of uterine rupture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based on the data described above and our own experience, we approach induction of women who want a trial of labor after previous cesarean delivery (TOLAC) as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with uncomplicated pregnancies, we strip (or sweep) membranes at 38 weeks of gestation to hasten the onset of spontaneous labor and thereby reduce the likelihood of postterm pregnancy and the interventions associated with its management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link&amp;anchor=H7537993#H7537993\">",
"       \"Principles of labor induction\", section on 'Membrane stripping'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with maternal or fetal indications for induction, we counsel the patient about the risks and benefits of induction versus repeat cesarean delivery, as well as the risks associated with awaiting spontaneous labor in this setting. Women who wish to minimize the risk of uterine rupture can reasonably choose repeat cesarean delivery rather than induction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link&amp;anchor=H18438373#H18438373\">",
"       \"Choosing the route of delivery after cesarean birth\", section on 'Optimum candidates for TOLAC'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with a favorable cervix who choose to be induced, we suggest amniotomy and administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Oxytocin induction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with an unfavorable cervix who choose to be induced, we discuss the risks and benefits of mechanical and pharmacologic options of cervical ripening, as well as labor induction and augmentation. We suggest mechanical cervical ripening followed by amniotomy and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      administration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cervical ripening with mechanical methods'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Oxytocin induction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Prostaglandins for cervical ripening/induction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       not",
"      </strong>",
"      using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      in women with prior cesarean deliveries (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Other prostaglandins can be considered, but sequential use of prostaglandins followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      administration may increase the risk of uterine rupture, and should be avoided. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prostaglandins for cervical ripening/induction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/1\">",
"      Jozwiak M, Dodd JM. Methods of term labour induction for women with a previous caesarean section. Cochrane Database Syst Rev 2013; :CD009792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/2\">",
"      Dodd JM, Crowther CA. Elective repeat caesarean section versus induction of labour for women with a previous caesarean birth. Cochrane Database Syst Rev 2006; :CD004906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/3\">",
"      Kayani SI, Alfirevic Z. Induction of labour with previous caesarean delivery: where do we stand? Curr Opin Obstet Gynecol 2006; 18:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/4\">",
"      McDonagh MS, Osterweil P, Guise JM. The benefits and risks of inducing labour in patients with prior caesarean delivery: a systematic review. BJOG 2005; 112:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/5\">",
"      Grobman WA, Gilbert S, Landon MB, et al. Outcomes of induction of labor after one prior cesarean. Obstet Gynecol 2007; 109:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/6\">",
"      Grobman WA, Lai Y, Landon MB, et al. Does information available at admission for delivery improve prediction of vaginal birth after cesarean? Am J Perinatol 2009; 26:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/7\">",
"      Landon MB, Hauth JC, Leveno KJ, et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med 2004; 351:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/8\">",
"      Harper LM, Cahill AG, Boslaugh S, et al. Association of induction of labor and uterine rupture in women attempting vaginal birth after cesarean: a survival analysis. Am J Obstet Gynecol 2012; 206:51.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/9\">",
"      Cahill AG, Stamilio DM, Odibo AO, et al. Does a maximum dose of oxytocin affect risk for uterine rupture in candidates for vaginal birth after cesarean delivery? Am J Obstet Gynecol 2007; 197:495.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/10\">",
"      Cahill AG, Waterman BM, Stamilio DM, et al. Higher maximum doses of oxytocin are associated with an unacceptably high risk for uterine rupture in patients attempting vaginal birth after cesarean delivery. Am J Obstet Gynecol 2008; 199:32.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/11\">",
"      American College of Obstetrics and Gynecology Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin Number 49, December 2003: Dystocia and augmentation of labor. Obstet Gynecol 2003; 102:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/12\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice bulletin no. 115: Vaginal birth after previous cesarean delivery. Obstet Gynecol 2010; 116:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/13\">",
"      Pettker CM, Pocock SB, Smok DP, et al. Transcervical Foley catheter with and without oxytocin for cervical ripening: a randomized controlled trial. Obstet Gynecol 2008; 111:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/14\">",
"      Lydon-Rochelle M, Holt VL, Easterling TR, Martin DP. Risk of uterine rupture during labor among women with a prior cesarean delivery. N Engl J Med 2001; 345:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Use of hospital discharge data to monitor uterine rupture--Massachusetts, 1990-1997. MMWR Morb Mortal Wkly Rep 2000; 49:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/16\">",
"      Macones GA, Peipert J, Nelson DB, et al. Maternal complications with vaginal birth after cesarean delivery: a multicenter study. Am J Obstet Gynecol 2005; 193:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/17\">",
"      Wing DA, Lovett K, Paul RH. Disruption of prior uterine incision following misoprostol for labor induction in women with previous cesarean delivery. Obstet Gynecol 1998; 91:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/18\">",
"      Sanchez-Ramos L, Gaudier FL, Kaunitz AM. Cervical ripening and labor induction after previous cesarean delivery. Clin Obstet Gynecol 2000; 43:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/19\">",
"      Sciscione AC, Nguyen L, Manley JS, et al. Uterine rupture during preinduction cervical ripening with misoprostol in a patient with a previous Caesarean delivery. Aust N Z J Obstet Gynaecol 1998; 38:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/20\">",
"      Plaut MM, Schwartz ML, Lubarsky SL. Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. Am J Obstet Gynecol 1999; 180:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/21\">",
"      Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. Guidelines for vaginal birth after previous caesarean birth. Number 155 (Replaces guideline Number 147), February 2005. Int J Gynaecol Obstet 2005; 89:319.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists Induction of labour. Evidence Based Clinical Guideline No. 9, Clinical Effectiveness Support Unit, RCOG, London, Royal College of Obstetricians and Gynaecologists 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/23\">",
"      Ravasia DJ, Wood SL, Pollard JK. Uterine rupture during induced trial of labor among women with previous cesarean delivery. Am J Obstet Gynecol 2000; 183:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/24\">",
"      Bujold E, Blackwell SC, Gauthier RJ. Cervical ripening with transcervical foley catheter and the risk of uterine rupture. Obstet Gynecol 2004; 103:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28535/abstract/25\">",
"      Hoffman MK, Sciscione A, Srinivasana M, et al. Uterine rupture in patients with a prior cesarean delivery: the impact of cervical ripening. Am J Perinatol 2004; 21:217.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4451 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28535=[""].join("\n");
var outline_f27_55_28535=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIKELIHOOD OF SUCCESSFUL INDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK OF UTERINE RUPTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oxytocin induction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2772734\">",
"      - Oxytocin for cervical ripening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prostaglandins for cervical ripening/induction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cervical ripening with mechanical methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/35/1591?source=related_link\">",
"      Diagnosis and management of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28053?source=related_link\">",
"      Insertion of intrauterine pressure catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/60/20418?source=related_link\">",
"      Patient information: Vaginal birth after cesarean delivery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/33/27155?source=related_link\">",
"      Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=related_link\">",
"      Techniques for ripening the unfavorable cervix prior to induction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_55_28536="Cytogenetic and molecular genetic diagnostic tools";
var content_f27_55_28536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cytogenetic and molecular genetic diagnostic tools",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28536/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28536/contributors\">",
"     Iris Schrijver, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28536/contributors\">",
"     James L Zehnder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28536/contributors\">",
"     Athena M Cherry, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28536/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28536/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28536/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28536/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/55/28536/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intense genetic research has exponentially increased our knowledge of the genetic code of humans and other organisms, leading to the development of numerous methods that facilitate our understanding of normal and abnormal genetic processes. Many of these methods and related techniques are now routinely used in the molecular diagnosis of both inherited disorders and diseases that result from somatic mutations, such as the hematologic malignancies. Molecular genetic and cytogenetic diagnostics are invaluable additions to laboratory testing and clinical evaluation, providing diagnostic, therapeutic, and prognostic information. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41049?source=see_link\">",
"     \"Genetic abnormalities in hematologic and lymphoid malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the advent of improved and faster molecular methods has transformed the traditional diagnostic process, keeping current with the most recent advances is daunting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/1\">",
"     1",
"    </a>",
"    ]. A conceptual approach to a selection of the most common standard and novel diagnostic tools will be applied to this review. An outline of the advantages and limitations of each of the techniques is included, as well as some examples of their applications. A brief introduction to the terms required to properly understand these applications is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link\">",
"     \"Principles of molecular genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three general categories of testing can be distinguished.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mutation detection",
"      </strong>",
"      of known sequence changes can be performed. This type of testing is targeted and typically limited to a predefined number of sequence changes, selected in advance. Selection is generally based on association with clinical phenotypes. Sequence changes may be located within a single gene or across multiple genes. Depending on the testing method used, the number of included sequence changes can range from a single mutation to thousands of mutations.",
"     </li>",
"     <li>",
"      <strong>",
"       Cytogenetic studies",
"      </strong>",
"      of large structural variants are typically performed when the phenotype does not seem limited to point mutations and relatively small deletions and duplications. Such studies are helpful in syndromic phenotypes and for constellations of symptoms typically associated with abnormalities on the scale of chromosomes rather than single exons or genes.",
"     </li>",
"     <li>",
"      <strong>",
"       Genotyping methods",
"      </strong>",
"      can be applied to identify mutations not selected in advance. These methods aim to discover mutations, and can target a gene with a known heterogeneous distribution of mutations, or can target larger segments of the genome to identify known or novel variations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5157832\">",
"    <span class=\"h1\">",
"     DETECTING KNOWN MUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many different approaches for the identification of selected, known mutations. Typically, these start with the polymerase chain reaction, after which additional assay steps are performed. The following section lists examples of some of the frequently used techniques, together with their advantages and disadvantages. General mutation detection methods such as DNA sequencing can also be applied to the identification of known mutations. Although the entire sequence in an amplified fragment would be read, mutations within that segment would be identified readily by this more comprehensive method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The automated polymerase chain reaction (PCR) is commonly the first step in the vast majority of DNA analyses because it increases the amount of DNA available for analysis. This important diagnostic tool is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/54/13159?source=see_link\">",
"     \"Polymerase chain reaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Restriction enzyme digestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restriction enzyme digestion can be used to detect mutations that create or destroy a restriction enzyme site. Specific restriction enzymes, usually isolated from bacteria, recognize unique short sequences within a DNA fragment. These enzymes can cleave the DNA strands at that exact site. If a mutation either changes the DNA code to a sequence that creates a new restriction enzyme site or obliterates an existing restriction enzyme site, the mutation can be detected based upon the presence or absence of the site (",
"    <a class=\"graphic graphic_figure graphicRef81760 \" href=\"UTD.htm?17/41/18077\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One example of such a test is a restriction digestion assay for Muenke syndrome, a type of craniosynostosis syndrome defined by a single mutation (c.749C&gt;G, p.Pro250Arg) in the FGFR3 gene that creates a new restriction site. In this assay, exon 7 is amplified by PCR, and the sample is subjected to a restriction digest with Ban I, the enzyme that recognizes the new site. DNA from patients who carry the mutation is cleaved by the enzyme, while control DNA lacking the mutation remains uncleaved.",
"   </p>",
"   <p>",
"    Advantages of this technique include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is technically easy and can be performed within one day.",
"     </li>",
"     <li>",
"      Restriction enzyme analysis detects specific mutations and can be applied to many samples concurrently. These samples are then run side-by-side on a single gel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This method is impractical for disorders caused by a large number of different mutations and for the detection of mutations associated with nucleotide sequences that require the use of expensive restriction enzymes.",
"     </li>",
"     <li>",
"      Only a small fraction of existing point mutations actually create or remove a restriction site. In some instances, this problem can be circumvented by the introduction of an artificial restriction site during PCR amplification [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Incomplete digestion can produce erroneous results. This problem can be overcome by using adequate controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Amplification refractory mutation system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amplification refractory mutation system (ARMS) can be used to detect known point mutations. This technique requires a multiplex PCR reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/3\">",
"     3",
"    </a>",
"    ]. In this reaction, two primer pairs are added to a single PCR tube and two separate sequences from one piece of DNA are amplified in the same reaction. One reaction (using the control primer pair) is an internal control to demonstrate that the PCR reaction itself has worked. The other reaction (using a primer pair specific for the mutation under study) will amplify the target sequence depending upon the presence or absence of a specific point mutation. A second tube contains DNA from the same patient, and includes the control primer pair and a primer pair that amplifies only the normal sequence. The only difference between the primers for the normal and mutant sequence is complementarity of one primer at the 3' end, where one is identical to the normal and one to the variant sequence. The other primer is the same for both reactions, and the product size will be the same. When run side by side on a gel, these samples will exhibit homozygosity for the normal sequence, homozygosity for the mutation, or heterozygosity (",
"    <a class=\"graphic graphic_figure graphicRef55076 \" href=\"UTD.htm?25/17/25886\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This assay is an actual modification of the PCR itself, rather than an additional step after the original amplification. ARMS can be performed for just one, or a small number of simultaneously tested mutations. An example is an ARMS test for BRAF mutation c.1799T&gt;A (p.V600E) which has been identified in colorectal carcinoma, melanoma, and papillary thyroid carcinoma. Because the mutation is a point mutation, changing one nucleotide to another, primers can be designed such that either the wild-type or the mutant sequence perfectly matches the very 3 prime end of the primer. In an optimized assay, a PCR product would then only be expected with the primer pair that entirely matches.",
"   </p>",
"   <p>",
"    Advantages of this technique include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is easy to perform and complete within one day.",
"     </li>",
"     <li>",
"      It can detect specific point mutations and assess many samples concurrently. Modification of the method allows analysis of several mutations in one test tube.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is impractical for disorders caused by a large number of mutations.",
"     </li>",
"     <li>",
"      Primer pairs must be designed for all reactions. Amplification of these reactions under the same conditions is a prerequisite. If the conditions are suboptimal for one of the primer pairs, weak amplification or nonspecific amplification may result in ambiguous results.",
"     </li>",
"     <li>",
"      Every patient sample requires multiple PCR tubes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Allele specific oligonucleotide hybridization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allele-specific oligonucleotide (ASO) hybridization involves the placing (\"spotting\") of denatured PCR-amplified DNA onto a membrane and subsequent hybridization with short allele-specific, labeled probes. Under optimal hybridization and washing conditions, hybridization will only occur if the probe sequence is perfectly complementary to the single-stranded sample DNA.",
"   </p>",
"   <p>",
"    Typically, PCR products from one patient sample are fixed onto two identical membranes (a \"dot-blot\"), one of which is hybridized with a probe that contains the normal sequence, while the other is hybridized with a probe for the mutant sequence. The two probes should differ by just one nucleotide, corresponding to the point mutation under investigation. After exposure to an autoradiographic film in the case of radioactive probe labeling, or after chemical treatment in the case of biotinylated oligomers, positive signals are scored and heterozygosity or homozygosity for the normal or mutant sequence can be determined (",
"    <a class=\"graphic graphic_figure graphicRef80013 \" href=\"UTD.htm?14/38/14958\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ASO hybridization can be modified to analyze a panel of mutations for a single patient. In \"reverse\" allele-specific hybridization, for example, sequence specific probes are spotted onto the membrane and only one membrane is used per patient. Reverse ASO is less cost-effective than regular ASO, but can decrease the turnaround time per sample. This method is frequently applied in molecular testing for cystic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H22#H22\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Molecular diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advantages of ASO hybridization include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is suitable for analysis of specific mutations or polymorphisms in numerous samples [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is highly sensitive and specific if properly optimized.",
"     </li>",
"     <li>",
"      Adaptations for multiplex PCR analysis or automated microarray (DNA chip) analysis are possible. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Amplification refractory mutation system'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2087689\">",
"       'Genotyping microarrays'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each ASO probe can only detect one specific sequence.",
"     </li>",
"     <li>",
"      ASO hybridization is amenable to small DNA mutations only.",
"     </li>",
"     <li>",
"      There is potential non-specificity if the hybridization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      washing conditions are not fully optimized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2087689\">",
"    <span class=\"h2\">",
"     Genotyping microarrays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotyping microarrays are available on a variety of different molecular platforms. They can all interrogate a flexible number of mutations at the same time, which makes them attractive for high throughput analyses in one or multiple genes, for one or many different patients at the same time. These assays are typically automated, and in a high-throughput setting (ie, automated analysis of multiple samples simultaneously), do not require hands-on work after the initiation of the assay run.",
"   </p>",
"   <p>",
"    Advantages of this method include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is suitable for high-throughput analysis of specific mutations or polymorphisms in numerous samples.",
"     </li>",
"     <li>",
"      Relatively less hands-on work is required per sample.",
"     </li>",
"     <li>",
"      Interpretation of the data can also be highly automated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The microarray analysis equipment as well as the individual arrays can be expensive.",
"     </li>",
"     <li>",
"      Often this method is not suitable for low-volume testing, in particular when the microarrays can be used only one time, regardless of whether only one or many samples are tested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15538597\">",
"    <span class=\"h1\">",
"     DETECTING CYTOGENETIC ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytogenetic abnormalities are genetic defects that involve large regions of chromosomes rather than small pieces of DNA (ie translocations, large deletions, or aneuploidies). These defects can be detected by at least three methods &ndash; chromosomal (karyotypic) analysis, fluorescence in situ hybridization (FISH) using specific DNA probes on either metaphase chromosomes or interphase nuclei, and array comparative genomic hybridization (aCGH). The latter two methods are considered &ldquo;molecular cytogenetics,&rdquo; because they can detect anomalies which are below the resolution of chromosomal analysis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15538624\">",
"    <span class=\"h2\">",
"     Chromosomal analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal analysis (also called chromosome banding) is used to detect changes in large regions of chromosomes (translocations, large deletions, or aneuploidies).",
"   </p>",
"   <p>",
"    To perform chromosome analysis, lymphocytes, usually obtained from the peripheral blood, are cultured in vitro and stimulated to divide under the influence of mitogens. Other cell types, such as amniocytes, bone marrow cells, fibroblasts, and tumor cells can also be analyzed, often without a mitogenic stimulus. Once the cells divide readily, a chemical is added to arrest mitotic division in metaphase. In this phase of the cell cycle, the chromosomes are maximally contracted and hence their banding patterns are easier to recognize (",
"    <a class=\"graphic graphic_figure graphicRef52419 \" href=\"UTD.htm?20/35/21040\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Chromosomal banding is then used to identify each individual chromosome, for assessment of whether the correct number of each chromosome is present (two of each autosome plus the sex chromosomes) and whether there are structural abnormalities. This technique can be performed using various enzymes and dyes. The most frequently used banding technique is GTG (G-banding with trypsin and Giemsa-banding) (",
"    <a class=\"graphic graphic_figure graphicRef81862 \" href=\"UTD.htm?13/22/13664\">",
"     figure 5",
"    </a>",
"    ). An identical banding pattern is seen in Q-banding, in which the chromosomes are stained with a fluorescent dye and viewed under ultraviolet illumination.",
"   </p>",
"   <p>",
"    The typical resolution of chromosome banding is about 400 bands in a haploid set of 23 chromosomes. A single chromosome band may contain 6 megabases (Mb) of DNA and approximately 150 genes. If higher banding resolution is desired to study relatively small chromosomal rearrangements, the cell cycles can be synchronized and cells arrested in prometaphase (550 bands) or even prophase (approximately 800 bands). The latter technique is called high resolution banding.",
"   </p>",
"   <p>",
"    Examples of the use of this method include evaluation of patients with acute myeloid leukemia (AML). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link\">",
"     \"Cytogenetics in acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many cases, chromosome banding has been replaced with alternative methods such as FISH and microarray analysis. (See",
"    <a class=\"local\" href=\"#H15538631\">",
"     'Fluorescence in situ hybridization'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15538652\">",
"     'Array comparative genomic hybridization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Advantages of chromosomal banding include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to molecular genetic studies, chromosome banding techniques show the entire genome at one time.",
"     </li>",
"     <li>",
"      This method is suitable in diagnostic situations where a specific anomaly is suspected (eg, the Philadelphia chromosome in chronic myeloid leukemia, CML). It may also be useful to monitor disease; for example, to detect additional chromosomal abnormalities commonly seen in disease progression of CML. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link&amp;anchor=H7228199#H7228199\">",
"       \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'Progression to acute phase CML'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In disorders having deletions of varying size within a specific chromosome, such as multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/5\">",
"       5",
"      </a>",
"      ], karyotypes from many patients can be compared, in order to find the critical disease-associated region (",
"      <a class=\"graphic graphic_figure graphicRef64638 \" href=\"UTD.htm?16/3/16446\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most chromosome banding techniques can only detect major structural abnormalities and will not detect smaller regions of DNA gain or loss.",
"     </li>",
"     <li>",
"      Interpretation is labor intensive and highly dependent upon operator experience and skill.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15538631\">",
"    <span class=\"h2\">",
"     Fluorescence in situ hybridization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluorescence in situ hybridization (FISH) is a technique that allows counting of the number and location of large pieces of chromosomes. This technique has greatly increased the sensitivity, specificity, and resolution of chromosome analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/6\">",
"     6",
"    </a>",
"    ]. FISH can be performed on metaphase chromosomes or interphase nuclei; interphase FISH can be done on paraffin embedded tissue.",
"   </p>",
"   <p>",
"    Metaphase FISH allows identification of large chromosomal abnormalities, including deletions, duplications, and translocations, as well as smaller chromosomal microdeletions and duplications. For metaphase FISH, cells are arrested in mitosis as for chromosomal banding. They are then fixed using a mixture of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    and methanol and then &ldquo;dropped&rdquo; on a glass microscope slide where they are affixed. DNA probes of a few hundred kilobases (kb) in length are used that match regions the chromosomes containing the DNA sequence in question. These probes are directly hybridized with the chromosomes on the slide (hence, the term \"in situ\" hybridization); immediate detection of the fluorescence signal is possible via fluorescence microscopy. Less commonly used isotopic and non-isotopic chemical labeling methods are also available (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67440 \" href=\"UTD.htm?25/7/25727\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    FISH probes produce a fluorescent dot on whichever chromosome they hybridize to. Thus, every pair of chromosomes (or chromosome regions) produces two dots. These double dots sometimes fuse to form one signal. Cells monosomic for the chromosomal region in question would show only a single dot per nucleus, while trisomic cells would show three dots.",
"   </p>",
"   <p>",
"    FISH can also be modified for analysis of interphase nuclei. (See",
"    <a class=\"local\" href=\"#H15538638\">",
"     'Interphase FISH'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Advantages of this technique are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The resolution of FISH is much better than traditional chromosome banding (FISH can resolve 2 megabases (Mb) in length, compared to 6 Mb for chromosomal banding).",
"     </li>",
"     <li>",
"      FISH can be applied to both dividing (metaphase) and non-dividing (interphase) cells.",
"     </li>",
"     <li>",
"      The protocol is technically fairly straightforward.",
"     </li>",
"     <li>",
"      Hybridization with multiple probes enables detection of translocation products. An example is the BCR-ABL1 fusion of t(9;22) in chronic myeloid leukemia (",
"      <a class=\"graphic graphic_figure graphicRef74102 \" href=\"UTD.htm?31/1/31761\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      FISH can identify a range of structural abnormalities including deletions, duplications, aneuploidy and the presence of derivative (structurally rearranged) chromosomes.",
"     </li>",
"     <li>",
"      FISH may be used to monitor recurrent or residual disease in bone marrow transplant patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=see_link&amp;anchor=H8#H8\">",
"       \"General aspects of cytogenetic analysis in hematologic malignancies\", section on 'FISH'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages of the technique are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small mutations, including small deletions and insertions as well as point mutations, cannot be identified.",
"     </li>",
"     <li>",
"      Uniparental disomy (inheritance of both copies of a chromosome from the same parent) will be missed because the probe merely detects the presence or absence of a locus or specific portion of a chromosome and not its source (",
"      <a class=\"graphic graphic_figure graphicRef72197 \" href=\"UTD.htm?12/1/12307\">",
"       figure 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Chromosomal inversions will be missed since a probe can only detect the presence of a specific sequence but not its precise location within the chromosome.",
"     </li>",
"     <li>",
"      Probes are not yet commercially available for all chromosomal regions.",
"     </li>",
"     <li>",
"      The clinician has to choose the correct FISH probe in order to make an accurate diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15538638\">",
"    <span class=\"h3\">",
"     Interphase FISH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interphase FISH is used when dividing cells are not available (eg, in fully differentiated cells or in tissues that have been fixed and embedded in paraffin). It also improves the resolution of FISH probes. For interphase FISH, cells are tested with FISH probes without cell cycle synchronization. When using intact nuclei (eg, not from paraffin embedded tissue), the cells are harvested using a hypotonic solution, fixed, and again &ldquo;dropped&rdquo; on the slides. For FISH on paraffin embedded tissue, thin slices of pathological specimens are cut and affixed to the slides.",
"   </p>",
"   <p>",
"    Because chromosomes are only minimally condensed in interphase, this modification of FISH analysis provides the opportunity to hybridize probes at a high resolution (well under 1 Mb, compared to 2 Mb for metaphase FISH). In the interphase nucleus, chromosomal structures cannot be discerned and only the hybridized probe will light up (",
"    <a class=\"graphic graphic_figure graphicRef60540 \" href=\"UTD.htm?23/41/24222\">",
"     figure 9",
"    </a>",
"    ). Hybridization with two different color probes that cross the breakpoint regions of genes involved in a translocation results in the expected signals from the normal chromosome as well as a fusion signal from the derived chromosome(s) on which the genes are juxtaposed by translocation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advantages of interphase FISH include the higher resolution than metaphase FISH; the ability to perform the test immediately without culturing the cells, which makes it faster; and the applicability to paraffin embedded sections. Interphase FISH is of special value in prenatal diagnosis of various aneuploidy states, such as trisomy 18 or trisomy 21, in which the ability to obtain results rapidly aids in decision making. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link&amp;anchor=H1497062#H1497062\">",
"     \"Diagnostic amniocentesis\", section on 'Fluorescence in situ hybridization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major disadvantage of interphase compared to metaphase FISH is that in interphase FISH the chromosomes themselves cannot be visualized. Thus, information cannot be provided regarding overall chromosome number and composition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15538645\">",
"    <span class=\"h3\">",
"     Spectral karyotyping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spectral karyotyping (SKY, also called multicolor FISH) is a FISH technique that accurately identifies the chromosomal origin of all elements in a karyogram (complete chromosome set) using multiple wavelengths of light to generate signals of many colors. A combination of five fluorochromes can be used as probes to \"paint\" all 22 autosomes, as well as the X and the Y chromosomes, in different colors (",
"    <a class=\"graphic graphic_figure graphicRef78864 \" href=\"UTD.htm?30/40/31362\">",
"     figure 10",
"    </a>",
"    ). The karyogram is analyzed by a computerized spectral imager and the chromosomes are classified based on their particular emission spectra [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advantages of this technique are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This method allows complete karyotyping using automated analysis.",
"     </li>",
"     <li>",
"      The origin of marker chromosomes, small insertions, and complex rearrangements can be inferred through the presence of color-coded chromosomal segments [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The equipment required may be prohibitively expensive for small diagnostic laboratories.",
"     </li>",
"     <li>",
"      Even though part of the analysis is computerized, the overall technique is labor intensive.",
"     </li>",
"     <li>",
"      Structural rearrangements within a single chromosome will not be detected.",
"     </li>",
"     <li>",
"      The resolution of SKY is relatively low (up to 15 Mb).",
"     </li>",
"     <li>",
"      SKY may be used when a specific abnormality is suspected, but is not applicable as a screening method.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15538652\">",
"    <span class=\"h2\">",
"     Array comparative genomic hybridization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparative genomic hybridization (CGH) allows detection of amplifications and deletions of smaller regions of DNA along the lengths of all of the chromosomes. The technique works by comparing the genomic content (or DNA) of a patient (or target) with a normal control individual (or individuals) (",
"    <a class=\"graphic graphic_figure graphicRef58888 \" href=\"UTD.htm?28/63/29687\">",
"     figure 11",
"    </a>",
"    ). The resolution of &ldquo;classical&rdquo; or metaphase CGH is relatively low (approximately 15 Mb of DNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Array CGH is a modification of CGH in which the comparator DNA, RNA, or tissue is arrayed on a glass slide or glass beads [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/12\">",
"     12",
"    </a>",
"    ]. There are three basic types of array: bacterial artificial chromosomes (BAC) arrays, oligonucleotide arrays (typically 60 base pairs in length), or single nucleotide polymorphism (SNP) arrays (typically a few nucleotides). Most SNP-based arrays now also include single locus probes as well as SNPs.",
"   </p>",
"   <p>",
"    There are at least two different types of arrays: &ldquo;targeted&rdquo; arrays and whole genomic arrays.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Targeted arrays &ldquo;target&rdquo; known",
"      <span class=\"nowrap\">",
"       microdeletion/microduplication",
"      </span>",
"      syndromes, as well as other known loci of inherited Mendelian disorders (eg, tuberous sclerosis). The first targeted arrays were arrays of around 500 to 600 BACs.",
"     </li>",
"     <li>",
"      Whole genomic arrays cover the entire genome at varying levels of resolution. The first whole genomic arrays were BAC arrays with around 2600 BACs spaced at about 1 Mb throughout the genome (ie, with about 1 Mb resolution). Oligonucleotide and SNP arrays have supplanted the use of BACs. Most laboratories use either oligonucleotide or SNP arrays with an average resolution of about 35 kb throughout the genome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both SNP and oligonucleotide arrays can detect copy number variations, but only SNP arrays can be used to determine whether there is absence or loss of heterozygosity (AOH or LOH) for different regions, or even entire chromosomes in the presence of normal copy number [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/13\">",
"     13",
"    </a>",
"    ]. AOH refers to the inheritance of either paternal or maternal alleles alone (",
"    <a class=\"graphic graphic_figure graphicRef72197 \" href=\"UTD.htm?12/1/12307\">",
"     figure 8",
"    </a>",
"    ). The absence of biparental inheritance can be seen in uniparental disomy (UPD) or in some cancer tissue samples. UPD can be the result of heterodisomy, in which two different homologous chromosomes from the same parent (either maternal or paternal) are present, instead of the normal biparental contribution (one chromosome from each parent). Alternatively, UPD can occur when there are two identical copies of a single parental chromosome (isodisomy). SNP arrays can only detect UPDs secondary to isodisomies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interpretation of array CGH can also be complicated by the presence of copy number variants (CNVs) that can be benign, pathogenic or unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=see_link&amp;anchor=H16722199#H16722199\">",
"     \"Genomic disorders: An overview\", section on 'Copy number variations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advantages of array CGH are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typically, dividing cells and tissue culture are not necessary; the technique requires only good, high quality DNA.",
"     </li>",
"     <li>",
"      Resolution of the array is dependent upon the type of array used and the average spacing of the &ldquo;probes&rdquo; on the array.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages of this technique are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Balanced structural rearrangements (ie balanced translocations, inversions, insertions) will not be detected, because there is no change in copy number.",
"     </li>",
"     <li>",
"      Levels of mosaicism (ie copy number changes in some but not all cells) of 20 percent or less will not be detected.",
"     </li>",
"     <li>",
"      Interpretation of copy number changes which have not been previously reported can be challenging, particularly if a phenotypically normal parent carries the same change.",
"     </li>",
"     <li>",
"      The technology is still relatively expensive, even though costs have declined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GENOTYPING NEW MUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In diseases with allelic heterogeneity, finding the disease-causing mutation is not straightforward. In these disorders, genes need to be scanned for mutations before a specific disease-causing mutation may be identified. After a new sequence variant has been detected and characterized, its pathogenicity must be established. This is commonly accomplished by screening a large number of normal controls, who are expected not to carry the same allelic variant. In addition, the DNA sequence of affected and unaffected individuals within the same family should be compared.",
"   </p>",
"   <p>",
"    Many methods of mutation screening are currently available, but the techniques described below are most widely applied. However, even the most common screening methods have limited application in clinical diagnostic laboratories, since the search for individual disease-causing mutations is a laborious and expensive process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Heteroduplex analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heteroduplex analysis is used to detect point mutations on one strand of a DNA helix. The technique uses denaturation and reannealing of the double stranded target DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/14\">",
"     14",
"    </a>",
"    ]. If complementary single strands re-anneal, they form a perfectly aligned homoduplex. On the other hand, single strands that are not completely complementary because of the presence of a point-mutation in one strand form a heteroduplex. The failure to anneal at all base positions results in the formation of a \"bubble\" in the newly formed double strand. As compared to normal DNA, DNA with a bubble migrates more slowly during electrophoresis. (",
"    <a class=\"graphic graphic_figure graphicRef55618 \" href=\"UTD.htm?9/48/9998\">",
"     figure 12",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This method is relatively easy to perform, and requires little optimization. Some of the available gel matrices are less toxic than polyacrylamide gels. A disadvantage is that this scanning method does not identify the location of the mutation within the analyzed fragment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Single strand conformation analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single strand conformation analysis (SSCA) is based on the observation that single-stranded DNA fragments assume unique conformations that depend on their sequence composition when run in a non-denaturing polyacrylamide gel. Migration through the gel thus depends on chain length as well as strand conformation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/15\">",
"     15",
"    </a>",
"    ]. Before interpretations can be made, the specific pattern of migration in wild-type control samples must be known. This can be achieved by the addition of normal controls in the run.",
"   </p>",
"   <p>",
"    Once optimized, this method is amenable to screening a fairly large number of samples at one time. However, this scanning method does not identify the location of the mutation within the analyzed fragment. SSCA also requires optimization, and reproducibility of the conditions in all analyses of the same DNA sequence is crucial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Automated sequencing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most direct approach to mutation detection is automated sequencing. A DNA sequence of interest is amplified in the presence of a primer and dideoxynucleotide chain terminators. Either the primer or the chain terminators are fluorescently labeled. As the sequence undergoes electrophoresis in an automated sequencer, a laser beam excites the fluorescent nucleotides, producing a signal that can be compiled into a DNA sequence (",
"    <a class=\"graphic graphic_figure graphicRef77662 \" href=\"UTD.htm?14/49/15120\">",
"     figure 13",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Advantages of this method include the precise identification of all DNA variations in the target sequence. Thus, the method can be applied to the detection of known mutations as well as to the identification of unknown mutations. For a large number of inherited conditions, new mutations continue to be discovered and add to the understanding of mutation spectra and genotype-phenotype correlations. Clinical testing is enhanced with the more comprehensive, inclusive testing approach.",
"   </p>",
"   <p>",
"    Disadvantages of the method include the financial cost, time, and the potential for poor quality data due to poor quality starting material. It should be noted that the finding of a previously uncharacterized point mutation does not mean the mutation has clinical significance. Clinical correlation of so-called &ldquo;variants of unknown significance&rdquo; (VUSs) can be challenging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1604356\">",
"    <span class=\"h3\">",
"     Whole genome sequencing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole genome sequencing allows identification of mutations in the entire genome, without the investigator having to choose a gene or chromosome region of interest. Improvements in the technology for high throughput sequencing continue to reduce the cost of this method. This method is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8777?source=see_link&amp;anchor=H2097381#H2097381\">",
"     \"Personalized medicine\", section on 'Next-generation sequencing (exome sequencing and whole genome sequencing)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As genome sequencing becomes available, more and more variants of unknown significance (VUSs) are expected to be identified. Clinical classification of these variants is likely to be a major challenge. Patients must be informed prior to testing that such VUSs will be identified, and though some may be clinically important (ie, confer disease risk), the current limits of medical knowledge preclude making definitive statements regarding their relevance to the patient&rsquo;s health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Southern and Northern blotting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Southern blotting can be used to detect small mutations as well as large deletions, duplications and gene rearrangements that alter restriction enzyme cleavage sites or the sizes of the resulting pieces of DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28536/abstract/16\">",
"     16",
"    </a>",
"    ]. In this technique, genomic DNA is digested with one or more restriction endonucleases and transferred to a membrane. This membrane is hybridized with a single-stranded radioactively labeled probe, under conditions that facilitate double-strand formation between the probe and those fragments on the gel containing the complementary sequence. When an autoradiographic film is exposed to the membrane and developed, the hybridized sequences become visible as bands. The location of each of these bands corresponds to the size of the fragment to which the probe is bound (",
"    <a class=\"graphic graphic_figure graphicRef78900 \" href=\"UTD.htm?27/40/28291\">",
"     figure 14",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A similar technique can be applied when RNA is the primary material. With this method, dubbed \"Northern blotting\", gene transcript size, abundance and expression patterns in different tissues can be analyzed.",
"   </p>",
"   <p>",
"    Advantages of these methods are the potential to detect a wide range of mutations and large structural rearrangements. Southern blotting can also be used to detect changes in gene methylation status (which affects sensitivity to restriction nucleotide digestion).",
"   </p>",
"   <p>",
"    Disadvantages include the requirement for larger amounts of DNA than the other methods mentioned herein, and the labor and time requirements. Generally, this assay can take a week to perform. The use of radioactive materials is both expensive and hazardous. However, nonradioactive methods, such as chemiluminescence, can be substituted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2103939\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytogenetic and molecular diagnostic tools are applied for three major purposes in clinical genetics: detecting specific mutations, studying large chromosomal structural variants, and genotyping to find mutations that have not been previously identified. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most tools to identify selected mutations involve polymerase chain reaction (PCR) technology. Techniques involving specific restriction enzymes can be used to find mutations that might affect the enzyme&rsquo;s target cleavage site, although only a small fraction of point mutations are amenable to such techniques. The amplification refractory mutation system (ARMS) involves a multiplex PCR reaction and can detect specific point mutations. Other techniques involve oligonucleotide hybridization and genotyping microarrays. Microarrays can allow for high throughput. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/54/13159?source=see_link\">",
"       \"Polymerase chain reaction\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5157832\">",
"       'Detecting known mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytogenetic analysis to identify large structural variation may involve chromosomal (karyotype) analysis by chromosomal banding; fluorescence in situ hybridization (FISH) on metaphase or interphase nuclei; or array comparative genomic hybridization (CGH). The resolution increases, meaning smaller and smaller genetic defects can be detected, from karyotyping to interphase FISH to array CGH. (See",
"      <a class=\"local\" href=\"#H15538597\">",
"       'Detecting cytogenetic abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For diseases with allelic heterogeneity, new sequence variants continue to be discovered. Methods that allow analysis of entire genes or genomes improve this discovery. Most methods for mutation screening have limited applicability in clinical diagnostic laboratories. The most direct approach to mutation detection is automated sequencing of the target DNA. Whole genome sequencing will likely become available in the near future at reasonable cost. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Genotyping new mutations'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/1\">",
"      Zamicnikova A. Genetic testing methods in myelodysplastic syndromes and leukemias: A review. Clin Leukemia 2007; 1:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/2\">",
"      Haliassos A, Chomel JC, Grandjouan S, et al. Detection of minority point mutations by modified PCR technique: a new approach for a sensitive diagnosis of tumor-progression markers. Nucleic Acids Res 1989; 17:8093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/3\">",
"      Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989; 17:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/4\">",
"      Schrijver I, Liu W, Francke U. The pathogenicity of the Pro1148Ala substitution in the FBN1 gene: causing or predisposing to Marfan syndrome and aortic aneurysm, or clinically innocent? Hum Genet 1997; 99:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/5\">",
"      Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000; 96:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/6\">",
"      van Ommen GJ, Breuning MH, Raap AK. FISH in genome research and molecular diagnostics. Curr Opin Genet Dev 1995; 5:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/7\">",
"      Haralambieva E, Banham AH, Bastard C, et al. Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples. Br J Haematol 2003; 121:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/8\">",
"      Schr&ouml;ck E, Veldman T, Padilla-Nash H, et al. Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities. Hum Genet 1997; 101:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/9\">",
"      Jalal SM, Law ME, Stamberg J, et al. Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization. Br J Haematol 2001; 112:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/10\">",
"      Hilgenfeld E, Padilla-Nash H, McNeil N, et al. Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukaemia M2. Br J Haematol 2001; 113:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/11\">",
"      Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/12\">",
"      Aradhya S, Cherry AM. Array-based comparative genomic hybridization: clinical contexts for targeted and whole-genome designs. Genet Med 2007; 9:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/13\">",
"      Papenhausen P, Schwartz S, Risheg H, et al. UPD detection using homozygosity profiling with a SNP genotyping microarray. Am J Med Genet A 2011; 155A:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/14\">",
"      Nagamine CM, Chan K, Lau YF. A PCR artifact: generation of heteroduplexes. Am J Hum Genet 1989; 45:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/15\">",
"      Hayashi K. PCR-SSCP: a method for detection of mutations. Genet Anal Tech Appl 1992; 9:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28536/abstract/16\">",
"      Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98:503.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2893 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28536=[""].join("\n");
var outline_f27_55_28536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2103939\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5157832\">",
"      DETECTING KNOWN MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Restriction enzyme digestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Amplification refractory mutation system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Allele specific oligonucleotide hybridization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2087689\">",
"      Genotyping microarrays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15538597\">",
"      DETECTING CYTOGENETIC ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15538624\">",
"      Chromosomal analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15538631\">",
"      Fluorescence in situ hybridization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15538638\">",
"      - Interphase FISH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15538645\">",
"      - Spectral karyotyping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15538652\">",
"      Array comparative genomic hybridization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GENOTYPING NEW MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Heteroduplex analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Single strand conformation analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Automated sequencing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1604356\">",
"      - Whole genome sequencing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Southern and Northern blotting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2103939\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2893\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2893|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/7/25727\" title=\"diagnostic image 1\">",
"      Microdeletion FISH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2893|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/41/18077\" title=\"figure 1\">",
"      RE digestion of PCR product",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/17/25886\" title=\"figure 2\">",
"      ARMS amplification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/38/14958\" title=\"figure 3\">",
"      ASO hybridization and dot blot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/35/21040\" title=\"figure 4\">",
"      Mitosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/22/13664\" title=\"figure 5\">",
"      Chromosomal banding GTG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/3/16446\" title=\"figure 6\">",
"      Chromosome 13 in myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/1/31761\" title=\"figure 7\">",
"      Complex rearrangement in CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/1/12307\" title=\"figure 8\">",
"      Uniparental disomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/41/24222\" title=\"figure 9\">",
"      Interphase FISH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/40/31362\" title=\"figure 10\">",
"      Spectral karyotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/63/29687\" title=\"figure 11\">",
"      Schematic CGH for microarray setup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/48/9998\" title=\"figure 12\">",
"      Heteroduplex analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/49/15120\" title=\"figure 13\">",
"      Automated DNA sequencing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/40/28291\" title=\"figure 14\">",
"      Southern blot hybridization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=related_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=related_link\">",
"      General aspects of cytogenetic analysis in hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41049?source=related_link\">",
"      Genetic abnormalities in hematologic and lymphoid malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=related_link\">",
"      Genomic disorders: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8777?source=related_link\">",
"      Personalized medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/54/13159?source=related_link\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_55_28537="Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis";
var content_f27_55_28537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28537/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28537/contributors\">",
"     Michael Frumovitz, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28537/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28537/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28537/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28537/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/55/28537/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of the uterine cervix is the third most common gynecologic cancer diagnosis and cause of death among gynecologic cancers in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/1\">",
"     1",
"    </a>",
"    ]. Cervical cancer has lower rates than uterine corpus and ovarian cancer, as well as many other cancer sites. These rankings are similar to global estimates for other developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/2\">",
"     2",
"    </a>",
"    ]. Unfortunately, in countries that do not have access to cervical cancer screening and prevention programs, cervical cancer remains the second most common type of cancer (17.8 per 100,000 women) and cause of cancer deaths (9.8 per 100,000) among all types of cancer in women.",
"   </p>",
"   <p>",
"    Human papillomavirus (HPV) is central to the development of cervical neoplasia and can be detected in 99.7 percent of cervical cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/3\">",
"     3",
"    </a>",
"    ]. The most common histologic types of cervical cancer are squamous cell (69 percent of cervical cancers) and adenocarcinoma (25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, clinical manifestations, and diagnosis of invasive cervical cancer will be reviewed here. Screening and prevention, staging, and the management of cervical cancer and preinvasive disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7674594\">",
"    <span class=\"h2\">",
"     Incidence and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globally, cervical cancer accounted for an estimated 530,000 new cancer cases worldwide and for 275,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/5\">",
"     5",
"    </a>",
"    ]. Eight-six percent of new cervical cancer cases will be seen in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/6\">",
"     6",
"    </a>",
"    ]. Worldwide, the mortality rate from cervical cancer is 52 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/6\">",
"     6",
"    </a>",
"    ]. Global incidence and mortality rates depend upon the presence of screening programs for cervical precancer and cancer and of human papillomavirus vaccination, which are most likely to be available in developed countries. Due to these interventions, there has been a 75 percent decrease in the incidence and mortality of cervical cancer over the past 50 years in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developed countries in 2008, cervical cancer was the tenth most common type of cancer in women (9.0 per 100,000 women) and ranked below the top ten causes of cancer mortality (3.2 per 100,000). In contrast, in developing countries it was the second most common type of cancer (17.8 per 100,000) and cause of cancer deaths (9.8 per 100,000) among women. On the continent of Africa and in Central America, cervical cancer is the number one cause of cancer-related mortality among women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19160?source=see_link\">",
"     \"Screening for cervical cancer in resource-limited settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, over 12,000 new cases of invasive cervical cancer and approximately 4000 cancer-related deaths occur each year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/1\">",
"     1",
"    </a>",
"    ]. Cervical cancer is the third most common cancer diagnosis and cause of death among gynecologic cancers in the United States, with lower rates than uterine corpus or ovarian cancer. Cervical cancer estimates are higher for certain racial and ethnic groups: whites (incidence:",
"    <span class=\"nowrap\">",
"     7.7/100,000",
"    </span>",
"    and mortality:",
"    <span class=\"nowrap\">",
"     2.2/100,000);",
"    </span>",
"    <span class=\"nowrap\">",
"     Hispanics/Latinos",
"    </span>",
"    <span class=\"nowrap\">",
"     (12.5/100,000",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     3.1/100,000);",
"    </span>",
"    African-Americans",
"    <span class=\"nowrap\">",
"     (10.7/100,000",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     4.4/100,000);",
"    </span>",
"    and American Indians and Alaska Natives",
"    <span class=\"nowrap\">",
"     (9.7/100,000",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     3.4/100,000)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7674822\">",
"    <span class=\"h2\">",
"     Age distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide in 2008, the cumulative risks of developing cervical cancer and of cervical cancer mortality by age 75 years were: developed countries (0.9 percent",
"    <span class=\"nowrap\">",
"     incidence/0.3",
"    </span>",
"    percent mortality) and developing countries (1.9",
"    <span class=\"nowrap\">",
"     percent/1.1",
"    </span>",
"    percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The lifetime risk of developing cervical cancer for United States women, based upon national data from 2000 to 2004, is 0.76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/4\">",
"     4",
"    </a>",
"    ]. The mean age at diagnosis of cervical cancer in the United States from 2000 to 2004 was 48 years. Only 5.7 percent of cases were diagnosed in women age 85 years or older. From 2000 to 2004, the United States age-adjusted incidence of cervical cancer in girls under age 20 was 0.1 per 100,000, rising to 1.5 per 100,000 in women age 20 to 24 years, and then ranging from 11.0 to 15.8 per 100,000 for women age 30 to over 85 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7674829\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major histologic types of cervical cancer, adenocarcinoma and squamous cell carcinoma, and the preinvasive disease that corresponds with these histologies share many of the same risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/10-20\">",
"     10-20",
"    </a>",
"    ]. Most of these are associated with an increased risk of acquiring or having appropriate compromised immune response to infection with human papillomavirus (HPV), the etiologic agent of most cervical cancers. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early onset of sexual activity &ndash; compared with age at first intercourse of 21 years or older, the risk is approximately 1.5-fold for 18 to 20 years and two-fold for younger than 18 years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Multiple sexual partners &ndash; compared with one partner, the risk is approximately two-fold with two partners and three-fold with 6 or more partners [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A high-risk sexual partner (eg, a partner with multiple sexual partners or known human papillomavirus infection)",
"     </li>",
"     <li>",
"      History of sexually transmitted infections (eg, Chlamydia trachomatis, genital herpes)",
"     </li>",
"     <li>",
"      History of vulvar or vaginal squamous intraepithelial neoplasia or cancer (HPV infection is also the etiology of most cases of these conditions)",
"     </li>",
"     <li>",
"      Immunosuppression (eg, human immunodeficiency virus infection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cervical cancer is less common in sexual partners of circumcised males [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=see_link&amp;anchor=H10#H10\">",
"     \"Neonatal circumcision: Risks and benefits\", section on 'Cervical cancer in partners'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early age at first birth (younger than 20 years old) and increasing parity (3 or more full term births) are also associated with an increased risk of cervical cancer, these are also likely due to exposure to HPV through sexual intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low socioeconomic status is associated with an increased risk of cervical cancer. From 1988 to 1992 in the United States, cervical cancer incidence was higher in women who lived in communities with higher poverty levels (&ge;20 percent or more of the population below the poverty level: 19.2 cases per 100,000 women versus &lt;10 percent below poverty level: 8.8 per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/21\">",
"     21",
"    </a>",
"    ]. Women in high compared with low poverty counties had a 71 percent higher rate of cervical cancer mortality.",
"   </p>",
"   <p>",
"    In the United States, cervical cancer incidence and mortality is higher in nonwhite than in white women, as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7674594\">",
"     'Incidence and mortality'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Oral contraceptive use has been reported to be associated with an increased risk of cervical cancer. A collaborative analysis of data from 24 epidemiological studies found that, among current users of oral contraceptives, the risk of invasive cervical cancer increased with increasing duration of use (&ge;5 years' use versus never-use: RR 1.90, 95% CI 1.69-2.13). The risk declined after use ceased, and by 10 or more years, had returned to that of never users [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/19\">",
"     19",
"    </a>",
"    ]. In the same study, use of oral contraceptives for 10 years from age 20 to 30 years was estimated to increase the cumulative incidence of invasive cervical cancer by age 50 from 7.3 to 8.3 per 1000 in developing countries and from 3.8 to 4.5 per 1000 in developed countries. While some studies suggest that adenocarcinoma appears to have a stronger association with oral contraceptives than does squamous cell cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/23\">",
"     23",
"    </a>",
"    ], others found a similar risk increase with increasing duration of oral contraceptives for both adeno- and squamous cell carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H23#H23\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Cervical cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to squamous cell cancer of the cervix, cigarette smoking is",
"    <strong>",
"     not",
"    </strong>",
"    associated with a significantly increased risk of adenocarcinoma of the cervix compared to nonsmokers (squamous cell carcinoma: RR 1.50, 95% CI 1.35&ndash;1.66; adenocarcinoma: RR 0.86, 95% CI 0.70&ndash;1.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/10,16\">",
"     10,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21103277\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no well-established model of a genetic basis for cervical cancer. Population studies have shown an increased incidence of cervical cancer within families. In the past, such familial clustering had been attributed to shared environmental exposures and risk factors. However, subsequent data comparing full and half siblings have concluded that heritable risk factors far outweigh the shared environmental components. As an example, a Swedish study of over 9000 siblings or half-siblings with cervical cancer or precancer attributed 64 percent of cases to genetics and only 36 percent to environmental exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigations are ongoing to identify genetic alterations that may make women less likely to clear persistent HPV infections and more susceptible to the development of cervical cancer. Findings to-date include an association of cervical cancer with a large variety of polymorphisms in a wide variety of genes including those that regulate immunity and susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/26\">",
"     26",
"    </a>",
"    ], cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], angiogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/27\">",
"     27",
"    </a>",
"    ], tumor suppressor pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], and signal transducer and activator of transcription (STAT) pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomavirus (HPV) is central to the development of cervical neoplasia and can be detected in 99.7 percent of cervical cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/3\">",
"     3",
"    </a>",
"    ]. The virology and molecular pathogenesis of HPV-associated malignancies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are four major steps in cervical cancer development [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oncogenic HPV infection of the metaplastic epithelium at the cervical transformation zone (the junction between the squamous epithelium of the ectocervix and the glandular epithelium of the endocervical canal)",
"     </li>",
"     <li>",
"      Persistence of the HPV infection",
"     </li>",
"     <li>",
"      Progression of a clone of epithelial cells from persistent viral infection to precancer",
"     </li>",
"     <li>",
"      Development of carcinoma and invasion through the basement membrane",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genital tract HPV infection is extremely common, but results in cervical cancer in only a small proportion of infected women. It has been estimated that 75 to 80 percent of sexually active adults will acquire genital tract HPV before the age of 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The disease burden of genital HPV infection includes conditions other than cervical cancer, including anogenital warts, and cancer of the vulva, vagina, anus, and penis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link&amp;anchor=H3#H3\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Role of human papillomavirus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the more than 40 genital mucosal HPV types identified, approximately 15 are known to be oncogenic (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"     table 1",
"    </a>",
"    ). Subtypes HPV 16 and 18 are found in over 70 percent of all cervical cancers.",
"   </p>",
"   <p>",
"    HPV plays a role primarily in the two most common histologic types of cervical cancer: squamous cell (69 percent of cervical cancers) and adenocarcinoma (25 percent) (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Histopathology'",
"    </a>",
"    below). The HPV subtypes associated with squamous cancer are different from those associated with adenocarcinoma. In an international study of over 30,000 cervical cancers, the distribution of HPV subtypes was [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Squamous cell carcinoma &ndash; HPV 16 (59 percent of cases); 18 (13 percent); 58 (5 percent); 33 (5 percent); 45 (4 percent)",
"     </li>",
"     <li>",
"      Adenocarcinoma &ndash; HPV 16 (36 percent); 18 (37 percent); 45 (5 percent); 31( 2 percent); 33 (2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most HPV infections are transient and the virus alone is not sufficient to cause cervical neoplasia. When HPV infection persists, the time from initial infection to development of high grade cervical intraepithelial neoplasia and, finally, invasive cancer takes an average of 15 years, although more rapid courses have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Herpes simplex virus-2 infection as a cofactor in cervical cancer pathogenesis has been reported in some, but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Further investigation of this issue is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic types of cervical cancer are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef65824 \" href=\"UTD.htm?2/38/2668\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/43\">",
"     43",
"    </a>",
"    ]. In the United States fr0m 2001 to 2004, the distribution of histologic types was [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Squamous cell carcinoma &ndash; 69 percent",
"     </li>",
"     <li>",
"      Adenocarcinoma (including adenosquamous) &ndash; 25 percent",
"     </li>",
"     <li>",
"      Other histologies &ndash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of invasive cervical adenocarcinoma and its variants has increased dramatically over the past few decades, particularly in younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Several causative factors have been proposed to explain this trend, including increased prevalence of specific HPV-16 and 18 variants that are associated more with adenocarcinoma than with squamous cell carcinoma as well as exposure to estrogens, both endogenous (eg, obesity ) and exogenous (eg, hormonal contraception, postmenopausal estrogen therapy).",
"   </p>",
"   <p>",
"    Adenosquamous tumors exhibit both glandular and squamous differentiation. They may be associated with a poorer outcome than squamous cell cancers or adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuroendocrine or small cell carcinomas can originate in the cervix in women, but are infrequent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/49\">",
"     49",
"    </a>",
"    ]. Rhabdomyosarcoma of the cervix is rare; it typically occurs in adolescents and young women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Primary cervical lymphoma and cervical sarcoma are also rare [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18327?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=see_link&amp;anchor=H1336437714#H1336437714\">",
"     \"Small cell neuroendocrine carcinoma of the cervix\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=see_link\">",
"     \"Invasive cervical adenocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087317\">",
"    <span class=\"h1\">",
"     ROUTES OF SPREAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer can spread by direct extension or by lymphatic or hematogenous dissemination. Direct extension may involve the uterine corpus, vagina, parametria, peritoneal cavity, bladder, or rectum. Ovarian involvement by direct extension of cervical cancer is rare; ovarian metastases occur in approximately 0.5 percent of squamous cell carcinomas and 1.7 percent of adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/55\">",
"     55",
"    </a>",
"    ]. The most common sites for hematogenous spread are the lungs, liver, and bone; the bowel, adrenal glands, spleen, and brain are less frequent sites.",
"   </p>",
"   <p>",
"    Historically, obturator lymph nodes were thought to be the most frequent site of nodal metastases in women with cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/56\">",
"     56",
"    </a>",
"    ]. It was also thought that lymphatic spread advanced in an orderly fashion from the lymph nodes on the pelvic sidewall to the common iliac, and then the paraaortic group (",
"    <a class=\"graphic graphic_figure graphicRef54775 \" href=\"UTD.htm?11/1/11289\">",
"     figure 1",
"    </a>",
"    ). However, subsequent studies, including those utilizing the sentinel lymph node mapping technique, emphasize that any of the pelvic lymph node groups, and even paraaortic lymph nodes, may contain the first draining lymph node and may be the first site of nodal metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. This was illustrated in a large retrospective study (n = 619) that evaluated women with cervical cancer patients who had solitary (one or two) positive lymph nodes discovered via radical hysterectomy and complete lymphadenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/59\">",
"     59",
"    </a>",
"    ]. The distribution of sites of nodal metastasis were: external iliac (43 percent), obturator (26 percent), parametrial (21 percent), common iliac (7 percent), presacral (1 percent), and paraaortic (1 percent).",
"   </p>",
"   <p>",
"    Sentinel node biopsy in cervical cancer is discussed in detail separately.",
"   </p>",
"   <p>",
"    The risk of pelvic lymph node metastasis increases with increasing depth of invasion, according to the International Federation of Gynecology and Obstetrics (FIGO) staging system (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 3",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/60-64\">",
"     60-64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage IAI &ndash; 0.2 percent",
"     </li>",
"     <li>",
"      Stage IA1 &ndash; 0.6 percent",
"     </li>",
"     <li>",
"      Stage IA2 &ndash; 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of paraaortic nodal involvement increases as the local disease extent increases:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage IB &ndash; 8 percent",
"     </li>",
"     <li>",
"      Stage IIA &ndash; 12 percent",
"     </li>",
"     <li>",
"      Stage IIB &ndash; 29 percent",
"     </li>",
"     <li>",
"      Stage IIIA &ndash; 17 percent",
"     </li>",
"     <li>",
"      Stage IIIB &ndash; 27 percent",
"     </li>",
"     <li>",
"      Stage IVA &ndash; 47 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early cervical cancer is frequently asymptomatic, underscoring the importance of screening. The most common symptoms at presentation are [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Irregular or heavy vaginal bleeding",
"     </li>",
"     <li>",
"      Postcoital bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some women present with a vaginal discharge that may be watery, mucoid, or purulent and malodorous. This is nonspecific finding and may be mistaken for vaginitis or cervicitis.",
"   </p>",
"   <p>",
"    Advanced disease may present with pelvic or lower back pain, which may radiate along the posterior side of the lower extremities. Bowel or urinary symptoms, such as pressure-related complaints, hematuria, hematochezia, or vaginal passage of urine or stool, are uncommon and suggest advanced disease.",
"   </p>",
"   <p>",
"    In asymptomatic women, cervical cancer may be discovered as a result of cervical cancer screening or incidentally, if a visible lesion is discovered upon pelvic examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1087482\">",
"     'Physical examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cervical cancer is made based upon histologic evaluation of a cervical biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087482\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pelvic examination should be performed in any woman with symptoms suggestive of cervical cancer. Visualization of the cervix upon speculum examination may reveal a normal appearance or a visible cervical lesion; large tumors may appear to replace the cervix entirely. Any lesion that is raised, friable, or has the appearance of condyloma should be biopsied, regardless of previous benign cervical cytology results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28537/abstract/66\">",
"     66",
"    </a>",
"    ]. The only visible lesions that do not require biopsy are Nabothian cysts, and only when this diagnosis is confirmed by an experienced examiner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link&amp;anchor=H13#H13\">",
"     \"Congenital cervical anomalies and benign cervical lesions\", section on 'Nabothian cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical cancer usually originates at the transformation zone (the junction between the squamous epithelium of the ectocervix and the glandular epithelium of the endocervical canal). The lesion may manifest as superficial ulceration, exophytic tumor in the exocervix, or infiltration of the endocervix. Endophytic tumors can result in an enlarged, indurated cervix whose surface is smooth, referred to as a &ldquo;barrel shaped cervix&rdquo;. Among cervical adenocarcinomas, approximately one-half are exophytic, others diffusely enlarge or ulcerate the cervix, and about 15 percent have no visible lesion because the carcinoma is within the endocervical canal.",
"   </p>",
"   <p>",
"    A thorough pelvic examination including rectovaginal examination with assessment of tumor size and vaginal or parametrial involvement is required for staging cervical cancer. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link&amp;anchor=H5#H5\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\", section on 'Staging procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other suspicious physical examination findings are palpable groin or supraclavicular lymph nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088023\">",
"    <span class=\"h2\">",
"     Cervical cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cytology is the principal method for cervical cancer screening. Cytology should also be performed for women with suspected cervical cancer. &nbsp;",
"   </p>",
"   <p>",
"    Cervical cancer screening, techniques for cervical cytology testing and interpretation of results are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=see_link\">",
"     \"Cervical cytology: Interpretation of results\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Human papillomavirus testing is used in combination with cervical cytology for cervical cancer screening and helps to determine which women with abnormal cytology results require further evaluation. However, it does not play a role in the diagnosis of malignancy in women with symptoms or a visible lesion suggestive of cervical cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H11#H11\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'HPV testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087497\">",
"    <span class=\"h2\">",
"     Cervical biopsy and colposcopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical biopsy may be performed as part of an initial evaluation or along with a full staging procedure, depending on the level of suspicion of malignancy and the patient&rsquo;s access to health care. The approach to cervical biopsy differs depending upon the patient&rsquo;s presentation and findings on pelvic examination: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women with a grossly visible lesion, a suspected diagnosis of cancer must be confirmed by a biopsy of the lesion. We prefer to take the biopsy from the area of the lesion that looks most suspicious with care to avoid grossly necrotic areas, as these are often non-diagnostic. Any cervix that is unusually firm or expanded should be sampled by punch biopsy and endocervical curettage, even if the cervical cytology test does not show evidence of neoplasia. Biopsy in women with gross lesions may result in significant bleeding and even hemorrhage, and practitioners should be adequately prepared with hemostatic agents such Monsel solution and the ability to pack the vagina should bleeding be significant.",
"     </li>",
"     <li>",
"      Women without a visible lesion (eg, symptomatic, abnormal cervical cytology) should undergo colposcopy with directed biopsy.",
"     </li>",
"     <li>",
"      Symptomatic women without a visible lesion and those who have only abnormal cervical cytology should undergo colposcopy with directed biopsy. An adequate colposcopy requires that the entire squamocolumnar junction and all lesions be completely visualized and that biopsies of the lesions explain the abnormal cytology. Women in settings in which colposcopy is not available may undergo directed biopsy with the aid of visual inspection methods. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"       \"Colposcopy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19160?source=see_link&amp;anchor=H8#H8\">",
"       \"Screening for cervical cancer in resource-limited settings\", section on 'Visual inspection methods'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Cervical conization is necessary if malignancy is suspected, but is not found with directed cervical biopsies (eg, some women with high-grade cervical intraepithelial neoplasia, inadequate colposcopy and in women with an endocervical curettage that is positive for moderate to severe dysplasia). Conization is also required in the setting of microinvasive cancer to determine whether conservative or radical surgery is required for treatment.",
"     </li>",
"     <li>",
"      Techniques for colposcopy and cervical biopsy and the staging evaluation for cervical cancer are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"       \"Colposcopy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"       \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088427\">",
"    <span class=\"h2\">",
"     Other diagnostic modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are not typically part of cervical cancer diagnosis, although some are used for staging and evaluation of women with known malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link&amp;anchor=H5#H5\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\", section on 'Staging procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link&amp;anchor=H6#H6\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\", section on 'Further evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cervical cancer includes other conditions that result in irregular or heavy vaginal bleeding, vaginal discharge, or a visible cervical lesion.",
"   </p>",
"   <p>",
"    Genital tract bleeding and vaginal discharge may be caused by a variety of conditions. Post-coital bleeding, which is the most specific presentation of cervical cancer, may also result from cervicitis. Evaluation of women with these conditions is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link\">",
"     \"Initial approach to the premenopausal woman with abnormal uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benign tumor-like lesions that may mimic cervical cancer include Nabothian cysts, mesonephric cysts, cervical ectropion, ulcers associated with sexually transmitted infections, reactive glandular changes from inflammation, and endometriosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link\">",
"     \"Congenital cervical anomalies and benign cervical lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3052581\">",
"    <span class=\"h1\">",
"     SCREENING AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of cervical cancer has declined significantly in settings in which cervical cancer screening is employed. In addition, human papillomavirus vaccination had been introduced to reduce the incidence of cervical neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=see_link\">",
"       \"Patient information: Cervical cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"       \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=see_link\">",
"       \"Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer of the uterine cervix is the third most common cancer diagnosis and cause of death among gynecologic cancers in the United States. In countries that do not have access to cervical cancer screening and prevention programs, cervical cancer remains the second most common type of cancer and cause of cancer deaths among all types of cancer in women. (See",
"      <a class=\"local\" href=\"#H7674594\">",
"       'Incidence and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lifetime risk of developing cervical cancer for United States women is 0.76 percent. The mean age at diagnosis of cervical cancer in the United States from is 48 years old. (See",
"      <a class=\"local\" href=\"#H7674822\">",
"       'Age distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human papillomavirus (HPV) is central to the development of cervical neoplasia and can be detected in 99.7 percent of cervical cancers. Subtypes HPV 16 and 18 are found in over 70 percent of all cervical cancers. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for cervical cancer are mostly associated with an increased risk of acquiring or having a compromised immune response to HPV infection; these include: early onset of sexual activity, multiple sexual partners, a high-risk sexual partner, history of sexually transmitted infections, history of vulvar or vaginal squamous intraepithelial neoplasia or cancer, immunosuppression. Oral contraceptive use appears to be associated with an increased risk of cervical cancer. Cigarette smoking appears to be associated with an increased risk of squamous cell cancer, but not adenocarcinoma. (See",
"      <a class=\"local\" href=\"#H7674829\">",
"       'Risk factors'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The most common histologic types of cervical cancer are squamous cell (69 percent of cervical cancers) and adenocarcinoma (25 percent). The histopathologic types of cervical cancer are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef65824 \" href=\"UTD.htm?2/38/2668\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early cervical cancer is frequently asymptomatic, emphasizing the importance of screening. The most common symptoms at presentation are: abnormal vaginal bleeding (including postcoital bleeding) and vaginal discharge. A lesion may or may not be visible or palpable on physical examination. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1087482\">",
"       'Physical examination'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      The diagnosis of cervical cancer is established by biopsy. Symptomatic women without a visible lesion and those who have only abnormal cervical cytology should undergo colposcopy with directed biopsy and, if necessary, diagnostic conization. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/2\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/3\">",
"      Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute; Bethesda, MD 2007.",
"    </li>",
"    <li>",
"     Cervical Cancer Incidence, Mortality and prevalence worldwide in 2008: Summary. file://globocan.iarc.fr/factsheet.asp (Accessed on January 30, 2013).",
"    </li>",
"    <li>",
"     WHO/ICO Information Center of HPV and Cervical Cancer (HPV Information Center). Human Papillomavirus and Related Cancers in the World. Summary Report 2010. file://www.who.int/hpvcentre/en/ (Accessed on September 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/7\">",
"      Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/8\">",
"      Willoughby BJ, Faulkner K, Stamp EC, Whitaker CJ. A descriptive study of the decline in cervical screening coverage rates in the North East and Yorkshire and the Humber regions of the UK from 1995 to 2005. J Public Health (Oxf) 2006; 28:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/9\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/10\">",
"      Berrington de Gonz&aacute;lez A, Green J, International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007; 120:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/11\">",
"      Castellsagu&eacute; X, Bosch FX, Mu&ntilde;oz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/12\">",
"      Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/13\">",
"      Wallin KL, Wiklund F, Luostarinen T, et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer 2002; 101:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/14\">",
"      Hawes SE, Kiviat NB. Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer? J Natl Cancer Inst 2002; 94:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/15\">",
"      Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002; 94:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/16\">",
"      International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/17\">",
"      Mu&ntilde;oz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/18\">",
"      International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006; 119:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/19\">",
"      International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/20\">",
"      Waggoner SE, Darcy KM, Tian C, Lanciano R. Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Am J Obstet Gynecol 2010; 202:283.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Singh GK, Miller BA, Hankey BF, Edwards BK. Area Socioeconomic Variations in U.S. Cancer Incidence, 1975-1999. National Cancer Institute; Bethesda, MD 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/22\">",
"      Saraiya M, Ahmed F, Krishnan S, et al. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol 2007; 109:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/23\">",
"      Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J 2003; 9:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/24\">",
"      Green J, Berrington de Gonzalez A, Sweetland S, et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer. Br J Cancer 2003; 89:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/25\">",
"      Hemminki K, Chen B. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev 2006; 15:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/26\">",
"      Liu L, Yang X, Chen X, et al. Association between TNF-&alpha; polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep 2012; 39:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/27\">",
"      Grimm C, Watrowski R, Baum&uuml;hlner K, et al. Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol 2011; 121:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/28\">",
"      Wang Q, Zhang C, Walayat S, et al. Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol 2011; 158:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/29\">",
"      Craveiro R, Bravo I, Catarino R, et al. The role of p73 G4C14-to-A4T14 polymorphism in the susceptibility to cervical cancer. DNA Cell Biol 2012; 31:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/30\">",
"      Wang L, Gao R, Yu L. Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk. Mol Biol Rep 2012; 39:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/31\">",
"      Wang K, Zhou B, Zhang J, et al. Association of signal transducer and activator of transcription 3 gene polymorphisms with cervical cancer in Chinese women. DNA Cell Biol 2011; 30:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/32\">",
"      Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/33\">",
"      Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis 2006; 33:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/34\">",
"      Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/35\">",
"      Kayes O, Ahmed HU, Arya M, Minhas S. Molecular and genetic pathways in penile cancer. Lancet Oncol 2007; 8:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/36\">",
"      Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24 Suppl 3:S3/11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/37\">",
"      Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/38\">",
"      Society of Gynecologic Oncologists Education Resource Panel Writing group, Collins Y, Einstein MH, et al. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol 2006; 102:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/39\">",
"      Jones C. Cervical cancer: is herpes simplex virus type II a cofactor? Clin Microbiol Rev 1995; 8:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/40\">",
"      Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/41\">",
"      Lehtinen M, Koskela P, Jellum E, et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. Am J Epidemiol 2002; 156:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/42\">",
"      Kjaer SK, de Villiers EM, Ca��layan H, et al. Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark)--a second look. Br J Cancer 1993; 67:830.",
"     </a>",
"    </li>",
"    <li>",
"     Kurman RJ, Norris HJ, Wilkinson EJ. Atlas of tumor pathology: Tumors of the cervix, vagina, and vulva, 3rd, Armed Forces Institute of Pathology, Washington, DC 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/44\">",
"      Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995; 59:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/45\">",
"      Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol 2000; 78:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/46\">",
"      Look KY, Brunetto VL, Clarke-Pearson DL, et al. An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 63:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/47\">",
"      Grisaru D, Covens A, Chapman B, et al. Does histology influence prognosis in patients with early-stage cervical carcinoma? Cancer 2001; 92:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/48\">",
"      Lea JS, Coleman RL, Garner EO, et al. Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol 2003; 91:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/49\">",
"      Albores-Saavedra J, Gersell D, Gilks CB, et al. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 1997; 121:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/50\">",
"      Behtash N, Mousavi A, Tehranian A, et al. Embryonal rhabdomyosarcoma of the uterine cervix: case report and review of the literature. Gynecol Oncol 2003; 91:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/51\">",
"      Villella JA, Bogner PN, Jani-Sait SN, et al. Rhabdomyosarcoma of the cervix in sisters with review of the literature. Gynecol Oncol 2005; 99:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/52\">",
"      Dursun P, Gultekin M, Bozdag G, et al. Primary cervical lymphoma: report of two cases and review of the literature. Gynecol Oncol 2005; 98:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/53\">",
"      Kendrick JE 4th, Straughn JM Jr. Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies. Gynecol Oncol 2005; 98:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/54\">",
"      Wright JD, Rosenblum K, Huettner PC, et al. Cervical sarcomas: an analysis of incidence and outcome. Gynecol Oncol 2005; 99:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/55\">",
"      Sutton GP, Bundy BN, Delgado G, et al. Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992; 166:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/56\">",
"      Pilleron JP, Durand JC, Hamelin JP. Prognostic value of node metastasis in cancer of the uterine cervix. Am J Obstet Gynecol 1974; 119:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/57\">",
"      Metcalf KS, Johnson N, Calvert S, Peel KR. Site specific lymph node metastasis in carcinoma of the cervix: Is there a sentinel node? Int J Gynecol Cancer 2000; 10:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/58\">",
"      Levenback C, Coleman RL, Burke TW, et al. Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol 2002; 20:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/59\">",
"      Bader AA, Winter R, Haas J, Tamussino KF. Where to look for the sentinel lymph node in cervical cancer. Am J Obstet Gynecol 2007; 197:678.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/60\">",
"      Lee YN, Wang KL, Lin MH, et al. Radical hysterectomy with pelvic lymph node dissection for treatment of cervical cancer: a clinical review of 954 cases. Gynecol Oncol 1989; 32:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/61\">",
"      Lagasse LD, Creasman WT, Shingleton HM, et al. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol Oncol 1980; 9:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/62\">",
"      Arends MJ, Buckley CH, Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol 1998; 51:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/63\">",
"      Hughes RR, Brewington KC, Hanjani P, et al. Extended field irradiation for cervical cancer based on surgical staging. Gynecol Oncol 1980; 9:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/64\">",
"      Sevin BU, Nadji M, Averette HE, et al. Microinvasive carcinoma of the cervix. Cancer 1992; 70:2121.",
"     </a>",
"    </li>",
"    <li>",
"     DiSaia PJ, Creasman WT. Invasive cervical cancer. In: Clinical Gynecologic Oncology, 7th ed., Mosby Elsevier, Philadelphia 2007. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28537/abstract/66\">",
"      Partridge EE, Abu-Rustum NR, Campos SM, et al. Cervical cancer screening. J Natl Compr Canc Netw 2010; 8:1358.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3179 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-08F48505D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28537=[""].join("\n");
var outline_f27_55_28537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7674594\">",
"      Incidence and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7674822\">",
"      Age distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7674829\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21103277\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1087317\">",
"      ROUTES OF SPREAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1087482\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1088023\">",
"      Cervical cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1087497\">",
"      Cervical biopsy and colposcopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1088427\">",
"      Other diagnostic modalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3052581\">",
"      SCREENING AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3179\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3179|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/1/11289\" title=\"figure 1\">",
"      Female pelvic and paraaortic lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3179|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/27/443\" title=\"table 1\">",
"      Risk of cervical CA with HPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/38/2668\" title=\"table 2\">",
"      Histopathology cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/6/33902\" title=\"table 3\">",
"      Staging cervical cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=related_link\">",
"      Cervical cytology: Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=related_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=related_link\">",
"      Invasive cervical adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=related_link\">",
"      Neonatal circumcision: Risks and benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=related_link\">",
"      Patient information: Cervical cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=related_link\">",
"      Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=related_link\">",
"      Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18327?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19160?source=related_link\">",
"      Screening for cervical cancer in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=related_link\">",
"      Small cell neuroendocrine carcinoma of the cervix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=related_link\">",
"      Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_55_28538="Approach to acute upper gastrointestinal bleeding in adults";
var content_f27_55_28538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to acute upper gastrointestinal bleeding in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28538/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28538/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28538/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28538/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/55/28538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/55/28538/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/55/28538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute upper gastrointestinal (GI) bleeding commonly present with hematemesis (vomiting of blood or coffee-ground like material)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    melena (black, tarry stools). The initial evaluation of patients with acute upper GI bleeding involves an assessment of hemodynamic stability and resuscitation if necessary. Diagnostic studies (usually endoscopy) follow, with the goal of both diagnosis, and when possible, treatment of the specific disorder.",
"   </p>",
"   <p>",
"    The diagnostic and initial therapeutic approach to patients with clinically significant (ie, the passage of more than a scant amount of blood) acute upper GI bleeding will be reviewed here. This approach is consistent with a multidisciplinary international consensus statement updated in 2010, a 2012",
"    <a class=\"external\" href=\"file://www.asge.org/WorkArea/showcontent.aspx?id=15156\">",
"     guideline",
"    </a>",
"    issued by the American Society for Gastrointestinal Endoscopy, and a 2012",
"    <a class=\"external\" href=\"file://s3.gi.org/physicians/guidelines/UlcerBleeding.pdf\">",
"     guideline",
"    </a>",
"    issued by the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The causes of upper GI bleeding, the endoscopic management of acute upper GI bleeding, and the management of active variceal hemorrhage are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12664?source=see_link\">",
"     \"Major causes of upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link\">",
"     \"Uncommon causes of upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"     \"General principles of the management of variceal hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A table outlining the emergency management of acute severe upper gastrointestinal bleeding is provided (",
"    <a class=\"graphic graphic_table graphicRef72195 \" href=\"UTD.htm?19/12/19661\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a patient with a suspected clinically significant acute upper GI bleed includes a history, physical examination, laboratory tests, and in some cases, nasogastric lavage. The goal of the evaluation is to assess the severity of the bleed, identify potential sources of the bleed, and determine if there are conditions present that may affect subsequent management. The information gathered as part of the initial evaluation is used to guide decisions regarding triage, resuscitation, empiric medical therapy, and diagnostic testing.",
"   </p>",
"   <p>",
"    Factors that are predictive of a bleed coming from an upper GI source identified in a meta-analysis included a patient-reported history of melena (likelihood ratio [LR] 5.1-5.9), melenic stool on examination (LR 25), blood or coffee grounds detected during nasogastric lavage (LR 9.6), and a ratio of blood urea nitrogen to serum creatinine greater than 30 (LR 7.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/5\">",
"     5",
"    </a>",
"    ]. On the other hand, the presence of blood clots in the stool made an upper GI source less likely (LR 0.05). Factors associated with severe bleeding included red blood detected during nasogastric lavage (LR 3.1), tachycardia (LR 4.9), or a hemoglobin level of less than 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (LR 4.5-6.2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H683979\">",
"    <span class=\"h2\">",
"     Bleeding manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematemesis (either red blood or coffee-ground emesis) suggests bleeding proximal to the ligament of Treitz. The presence of frankly bloody emesis suggests moderate to severe bleeding that may be ongoing, whereas coffee-ground emesis suggests more limited bleeding.",
"   </p>",
"   <p>",
"    The majority of melena (black, tarry stool) originates proximal to the ligament of Treitz (90 percent), though it may also originate from the small bowel or right colon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/6\">",
"     6",
"    </a>",
"    ]. Melena may be seen with variable degrees of blood loss, being seen with as little as 50 mL of blood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematochezia (red or maroon blood in the stool) is usually due to lower GI bleeding. However, it can occur with massive upper GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/8\">",
"     8",
"    </a>",
"    ], which is typically associated with orthostatic hypotension. (See",
"    <a class=\"local\" href=\"#H684000\">",
"     'Physical examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684310\">",
"    <span class=\"h2\">",
"     Past medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be asked about prior episodes of upper GI bleeding, since up to 60 percent of patients with a history of an upper GI bleed are bleeding from the same lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, the patient's past medical history should be reviewed to identify important comorbid conditions that may lead to upper GI bleeding or may influence the patient's subsequent management.",
"   </p>",
"   <p>",
"    Potential bleeding sources suggested by a patient's past medical history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Varices or portal hypertensive gastropathy in a patient with a history of liver disease or alcohol abuse",
"     </li>",
"     <li>",
"      Aorto-enteric fistula in a patient with a history of an abdominal aortic aneurysm or an aortic graft",
"     </li>",
"     <li>",
"      Angiodysplasia in a patient with renal disease, aortic stenosis, or hereditary hemorrhagic telangiectasia",
"     </li>",
"     <li>",
"      Peptic ulcer disease in a patient with a history of Helicobacter pylori or smoking",
"     </li>",
"     <li>",
"      Malignancy in a patient with a history of smoking, alcohol abuse, or H. pylori infection",
"     </li>",
"     <li>",
"      Marginal ulcers(ulcers at an anastomotic site) in a patient with a gastroenteric anastomosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comorbid illnesses may influence patient management in the setting of an acute upper GI bleed. Comorbid illnesses may:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Make patients more susceptible to hypoxemia (eg, coronary artery disease, pulmonary disease). Such patients may need to be maintained at higher hemoglobin levels than patients without these disorders. (See",
"      <a class=\"local\" href=\"#H5079586\">",
"       'Blood transfusions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Predispose patients to volume overload in the setting of fluid resuscitation or blood transfusions (eg, renal disease, heart failure). Such patients may need more invasive monitoring during resuscitation. (See",
"      <a class=\"local\" href=\"#H5079990\">",
"       'General support'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Result in bleeding that is more difficult to control (eg, coagulopathies, thrombocytopenia, significant hepatic dysfunction). Such patients may need transfusions of fresh frozen plasma or platelets. (See",
"      <a class=\"local\" href=\"#H5079586\">",
"       'Blood transfusions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Predispose to aspiration (eg, dementia, hepatic encephalopathy). Endotracheal intubation should be considered in such patients. (See",
"      <a class=\"local\" href=\"#H5079990\">",
"       'General support'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684391\">",
"    <span class=\"h2\">",
"     Medication history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough medication history should be obtained, with particular attention paid to drugs that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predispose to peptic ulcer formation, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and other nonsteroidal antiinflammatory drugs (NSAIDs) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"       \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Are associated with pill esophagitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=see_link\">",
"       \"Medication-induced esophagitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Promote bleeding, such as antiplatelet agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) and anticoagulants",
"     </li>",
"     <li>",
"      May alter the clinical presentation, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"       bismuth",
"      </a>",
"      and iron, which can turn the stool black",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H683993\">",
"    <span class=\"h2\">",
"     Symptom assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be asked about symptoms as part of the assessment of the severity of the bleed and as a part of the evaluation for potential bleeding sources. Symptoms that suggest the bleeding is severe include orthostatic dizziness, confusion, angina, severe palpitations, and",
"    <span class=\"nowrap\">",
"     cold/clammy",
"    </span>",
"    extremities.",
"   </p>",
"   <p>",
"    Specific causes of upper GI bleeding may be suggested by the patient's symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peptic ulcer: Epigastric or right upper quadrant pain",
"     </li>",
"     <li>",
"      Esophageal ulcer: Odynophagia, gastroesophageal reflux, dysphagia",
"     </li>",
"     <li>",
"      Mallory-Weiss tear: Emesis, retching, or coughing prior to hematemesis",
"     </li>",
"     <li>",
"      Variceal hemorrhage or portal hypertensive gastropathy: Jaundice, weakness, fatigue, anorexia, abdominal distention",
"     </li>",
"     <li>",
"      Malignancy: Dysphagia, early satiety, involuntary weight loss, cachexia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684000\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination is a key component of the assessment of hemodynamic stability. Signs of hypovolemia include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild to moderate hypovolemia: Resting tachycardia",
"     </li>",
"     <li>",
"      Blood volume loss of at least 15 percent: Orthostatic hypotension (a decrease in the systolic blood pressure of more than 20 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an increase in heart rate of 20 beats per minute when moving from recumbency to standing)",
"     </li>",
"     <li>",
"      Blood volume loss of at least 40 percent: Supine hypotension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination of the stool color may provide a clue to the location of the bleeding, but it is not a reliable indicator. In a series of 80 patients with severe hematochezia (red or maroon blood in the stool), 74 percent had a colonic lesion, 11 percent had an upper GI lesion, 9 percent had a presumed small bowel source, and no site was identified in 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/8\">",
"     8",
"    </a>",
"    ]. Nasogastric lavage may be carried out if there is doubt as to whether a bleed originates from the upper GI tract. (See",
"    <a class=\"local\" href=\"#H5079470\">",
"     'Nasogastric lavage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The presence of abdominal pain, especially if severe and associated with rebound tenderness or involuntary guarding, raises concern for perforation. If any signs of an acute abdomen are present, further evaluation to exclude a perforation is required prior to endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'Surgical abdomen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, as with the past medical history, the physical examination should include a search for evidence of significant comorbid illnesses. (See",
"    <a class=\"local\" href=\"#H684310\">",
"     'Past medical history'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079205\">",
"    <span class=\"h2\">",
"     Laboratory data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests that should be obtained in patients with acute upper gastrointestinal bleeding include a complete blood count, serum chemistries, liver tests, and coagulation studies. In addition, serial electrocardiograms and cardiac enzymes may be indicated in patients who are at risk for a myocardial infarction, such as the elderly, patients with a history of coronary artery disease, or patients with symptoms such as chest pain or dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial hemoglobin in patients with acute upper GI bleeding will often be at the patient's baseline because the patient is losing whole blood. With time (typically after 24 hours or more) the hemoglobin will decline as the blood is diluted by the influx of extravascular fluid into the vascular space and by fluid administered during resuscitation. It should be kept in mind that overhydration can lead to a falsely low hemoglobin value. The initial hemoglobin level is monitored every two to eight hours, depending upon the severity of the bleed.",
"   </p>",
"   <p>",
"    Patients with acute bleeding should have normocytic red blood cells. Microcytic red blood cells or iron deficiency anemia suggest chronic bleeding. Because blood is absorbed as it passes through the small bowel and patients may have decreased renal perfusion, patients with acute upper GI bleeding typically have an elevated blood urea nitrogen (BUN)-to-creatinine or urea-to-creatinine ratio (&gt;20:1 or &gt;100:1, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The higher the ratio, the more likely the bleeding is from an upper GI source [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079470\">",
"    <span class=\"h2\">",
"     Nasogastric lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether all patients with suspected acute upper GI bleeding require nasogastric tube (NGT) placement is controversial, in part because studies have failed to demonstrate a benefit with regard to clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/12\">",
"     12",
"    </a>",
"    ]. As an example, a retrospective study looked at whether there were clinical benefits from NGT lavage in 632 patients admitted with gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients who underwent NGT lavage were matched with patients with similar characteristics who did not undergo NGT lavage. NGT lavage was associated with a shorter time to endoscopy. However, there were no differences between those who underwent NGT lavage and those who did not with regard to mortality, length of hospital stay, surgery, or transfusion requirement.",
"   </p>",
"   <p>",
"    More often, NGT lavage is used when it is unclear if a patient has ongoing bleeding and thus might benefit from an early endoscopy. In addition, nasogastric tube lavage can be used to remove particulate matter, fresh blood, and clots from the stomach to facilitate endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=see_link&amp;anchor=H522921948#H522921948\">",
"     \"Nasogastric and nasoenteric tubes\", section on 'Tube placement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of red blood or coffee ground material in the aspirate also confirms an upper GI source of bleeding and predicts whether the bleeding is caused by a lesion at increased risk for ongoing or recurrent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, lavage may not be positive if bleeding has ceased or arises beyond a closed pylorus. The presence of nonbloody bilious fluid suggests that the pylorus is open and that there is no active upper GI bleeding distal to the pylorus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that patients only undergo NGT lavage if particulate matter, fresh blood, or clots need to be removed from the stomach to facilitate endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079565\">",
"    <span class=\"h2\">",
"     Triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with hemodynamic instability (shock, orthostatic hypotension) or active bleeding (manifested by hematemesis, bright red blood per nasogastric tube, or hematochezia) should be admitted to an intensive care unit for resuscitation and close observation with automated blood pressure monitoring, electrocardiogram monitoring, and pulse oximetry.",
"   </p>",
"   <p>",
"    A table outlining the emergency management of acute severe upper gastrointestinal bleeding is provided (",
"    <a class=\"graphic graphic_table graphicRef72195 \" href=\"UTD.htm?19/12/19661\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other patients can be admitted to a regular medical ward, though we suggest that all admitted patients with the exception of low-risk patients receive electrocardiogram monitoring. Outpatient management may be appropriate for some low-risk patients. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Risk stratification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079990\">",
"    <span class=\"h2\">",
"     General support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should receive supplemental oxygen by nasal cannula and should receive nothing per mouth. Two large caliber (16 gauge or larger) peripheral intravenous catheters or a central venous line should be inserted and placement of a pulmonary artery catheter should be considered in patients with hemodynamic instability or who need close monitoring during resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elective endotracheal intubation in patients with ongoing hematemesis or altered respiratory or mental status may facilitate endoscopy and decrease the risk of aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079572\">",
"    <span class=\"h2\">",
"     Fluid resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate resuscitation and stabilization is essential prior to endoscopy to minimize treatment-associated complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with active bleeding should receive intravenous fluids (eg, 500 mL of normal saline over 30 minutes) while being typed and cross-matched for blood transfusion. Patients at risk of fluid overload may require intensive monitoring with a pulmonary artery catheter.",
"   </p>",
"   <p>",
"    If the blood pressure fails to respond to initial resuscitation efforts, the rate of fluid administration should be increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079586\">",
"    <span class=\"h2\">",
"     Blood transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to initiate blood transfusions must be individualized. Our approach is to initiate blood transfusions if the hemoglobin is &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for patients who do not have significant comorbid illnesses, with a goal of maintaining the hemoglobin at a level &ge;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/4,16,17\">",
"     4,16,17",
"    </a>",
"    ]. However, our goal is to maintain the hemoglobin at a level of &ge;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for patients at increased risk of suffering adverse events in the setting of significant anemia, such as those with unstable coronary artery disease. We do not have an age cutoff for determining which patients should have a goal hemoglobin of &ge;9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and instead base the decision on the patient's comorbid conditions. However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. (See",
"    <a class=\"local\" href=\"#H5079205\">",
"     'Laboratory data'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is particularly important to avoid overtransfusion in patients with suspected variceal bleeding, as it can precipitate worsening of the bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. Transfusing patients with suspected variceal bleeding to a hemoglobin &gt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link&amp;anchor=H5#H5\">",
"     \"General principles of the management of variceal hemorrhage\", section on 'Hemodynamic resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial suggests that using a lower hemoglobin threshold for initiating transfusion improves outcomes. In the trial, 921 adults with acute upper GI bleeding were assigned to either a restrictive transfusion strategy (transfusion only when the hemoglobin fell to &lt;7",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    or a liberal transfusion strategy (transfusion when the hemoglobin fell to &lt;9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients were excluded if they had massive exsanguinating bleeding, an acute coronary syndrome, symptomatic peripheral vasculopathy, stroke, transient ischemic attack, transfusion within the prior 90 days, recent trauma or surgery, a Rockall score of 0 with a hemoglobin level higher than 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (patients at low risk of further bleeding), or if the attending clinician previously decided that a patient should avoid a specific medical therapy. Older age was not an exclusion criterion, and the mean age of patients was 64 years in the restrictive group and 66 years in the liberal group. In addition, cirrhosis was not an exclusion criterion (31 percent of the patients in the study had cirrhosis). The majority of patients in the restrictive and liberal transfusion groups had bleeding due to a peptic ulcer (51 and 47 percent, respectively), followed by variceal bleeding (23 and 24 percent, respectively).",
"   </p>",
"   <p>",
"    Patients in the restrictive group were more likely than those in the liberal group to avoid transfusion (51 versus 14 percent) and received fewer units of blood (mean 1.5 versus 3.8 units). Mortality was lower in the restrictive strategy group (5 versus 9 percent, adjusted hazard ratio 0.55, 95% confidence interval 0.33-0.92). Patients in the restrictive group were also less likely to have further bleeding or to suffer complications. Among patients with cirrhosis, the risks of death and further bleeding were lower with the restrictive strategy for patients with Child A or B cirrhosis, but were similar for patient with Child C cirrhosis.",
"   </p>",
"   <p>",
"    It is important to note, however, that all the patients in this study underwent emergent upper endoscopy with a mean duration from admission to upper endoscopy of 5 hours. Endoscopic therapy was given to those with active bleeding, a nonbleeding visible vessel, an adherent clot, or bleeding esophageal varices. It is not clear whether similar results would be seen in patients who do not receive an upper endoscopy and endoscopic therapy as quickly as the patients included in this study. Theoretically, patients treated with a restrictive transfusion strategy may have worse outcomes in the setting of delayed endoscopy with ongoing bleeding.",
"   </p>",
"   <p>",
"    A retrospective study also suggested that outcomes may be worse in patients who receive blood transfusions. The study included 1677 patients with nonvariceal upper GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/22\">",
"     22",
"    </a>",
"    ]. While not associated with mortality, blood transfusion within the first 24 hours of presentation was independently associated with an increased risk of rebleeding after adjusting for factors such as hemodynamic instability, endoscopic therapy, high-risk stigmata of recurrent hemorrhage, initial hemoglobin value, and the presence of blood on rectal examination or in the nasogastric tube aspirate (OR 1.8, 95% CI 1.2-2.8).",
"   </p>",
"   <p>",
"    Patients with active bleeding and a coagulopathy (prolonged prothrombin time with INR &gt;1.5) or low platelet count",
"    <span class=\"nowrap\">",
"     (&lt;50,000/microL)",
"    </span>",
"    should be transfused with fresh frozen plasma (FFP) or platelets, respectively. Provided the patient is hemodynamically stable, urgent endoscopy can usually proceed simultaneously with transfusion and should not be postponed until the coagulopathy is corrected. However, in patients with an INR &ge;3, we attempt to correct the INR to &lt;3 prior to starting an endoscopy, with additional FFP being given during the endoscopy if the INR is still &gt;1.5. This approach is based on data that suggest endoscopy is safe in patients who are mildly to moderately anticoagulated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, because packed red blood cells do not contain coagulation factors, transfusion of a unit of FFP should be considered after every four units of packed red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelet transfusions should also be considered in patients with life-threatening bleeding who have received antiplatelet agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/25\">",
"     25",
"    </a>",
"    ]. If the patient is taking the medications because of a recent (&lt;1 year) vascular stent placement or acute coronary syndrome, when possible, a cardiologist should be consulted prior to stopping the agent or giving a platelet transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079594\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079756\">",
"    <span class=\"h3\">",
"     Acid suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients admitted to the hospital with acute upper GI bleeding are typically treated with a proton pump inhibitor (PPI). We suggest that patients with acute upper GI bleeding be started empirically on an intravenous PPI. It can be started at presentation and continued until confirmation of the cause of bleeding. Once the source of the bleeding has been identified and treated (if possible), the need for ongoing acid suppression can be determined.",
"   </p>",
"   <p>",
"    Several studies have examined the role of acid suppression given before or after endoscopy (with or without therapeutic intervention) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/26\">",
"     26",
"    </a>",
"    ]. In the setting of active upper GI bleeding from an ulcer, acid suppressive therapy with H2 receptor antagonists has",
"    <strong>",
"     not",
"    </strong>",
"    been shown to significantly lower the rate of ulcer rebleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. By contrast, high dose antisecretory therapy with an intravenous infusion of a PPI significantly reduces the rate of rebleeding compared with standard treatment in patients with bleeding ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/30\">",
"     30",
"    </a>",
"    ]. Oral and intravenous PPI therapy also decrease the length of hospital stay, rebleeding rate, and need for blood transfusion in patients with high-risk ulcers treated with endoscopic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H57224540#H57224540\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Acid suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PPIs may also promote hemostasis in patients with lesions other than ulcers. This likely occurs because neutralization of gastric acid leads to the stabilization of blood clots [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An intravenous PPI given before endoscopic therapy in patients with acute upper GI bleeding can reduce signs of bleeding and the need for endoscopic therapy. One of the most methodologically rigorous controlled trials evaluating this approach included 638 patients with acute upper GI bleeding who were randomly assigned to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    or placebo before endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients randomized to omeprazole had significantly shorter lengths of stay, fewer actively bleeding ulcers (6 versus 15 percent), and more ulcers with a clean base. There was no significant difference in the proportion needing surgery or with recurrent bleeding. A possible limitation of the study is that multiple outcomes were examined, without a statistical correction for the multiple comparisons. In a cost-effectiveness analysis, administering an intravenous PPI before endoscopy was slightly more costly and effective than administering it after endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    has been the most extensively studied intravenous PPI, other intravenous formulations given in doses that are known to inhibit gastric acid secretion are probably acceptable alternatives.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     Pantoprazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    are the only intravenous formulations available in the United States, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    , which was previously available, has been removed from the world market. The suggested dose of intravenous pantoprazole is 80 mg bolus followed by 8",
"    <span class=\"nowrap\">",
"     mg/hr",
"    </span>",
"    infusion. Omeprazole and esomeprazole have also been used as 80 mg boluses followed by 8",
"    <span class=\"nowrap\">",
"     mg/hr",
"    </span>",
"    infusions. The infusion is usually continued for 72 hours. If there is no rebleeding the patient may be switched to oral pantoprazole 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or omeprazole 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Twice daily dosing of an oral proton pump inhibitor may be a reasonable alternative if intravenous formulations are not available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H57226173#H57226173\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'High-dose versus non-high-dose PPIs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079922\">",
"    <span class=\"h3\">",
"     Prokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    have been studied in patients with acute upper GI bleeding. The goal of using a prokinetic agent is to improve gastric visualization at the time of endoscopy by clearing the stomach of blood, clots, and food residue. We suggest that erythromycin be considered in patients who are likely to have a large amount of blood in their stomach, such as those with severe bleeding. A reasonable dose is 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously over 20 to 30 minutes, 30 to 90 minutes prior to endoscopy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    promotes gastric emptying based upon its ability to be an agonist of motilin receptors. Using erythromycin to improve gastric visualization has been studied in at least four randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. The studies suggested that a single dose of intravenous erythromycin given 20 to 120 minutes before endoscopy can significantly improve visibility, shorten endoscopy time, and reduce the need for second-look endoscopy. Treatment appears to be safe.",
"   </p>",
"   <p>",
"    A meta-analysis examined five trials with 316 patients who were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/38\">",
"     38",
"    </a>",
"    ]. The analysis found that the use of a prokinetic agent decreased the need for second-look endoscopy, but did not affect the number of units of blood transfused, length of hospital stay, or need for surgery. In subgroup analyses, erythromycin continued to show a benefit with regard to the need for second-look endoscopy, but metoclopramide did not.",
"   </p>",
"   <p>",
"    A second meta-analysis examined four trials with 335 patients who were assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/39\">",
"     39",
"    </a>",
"    ]. The meta-analysis found that patients who received erythromycin were significantly more likely to have an empty stomach at the time of endoscopy compared with patients in the control group (69 versus 37 percent). Patients treated with erythromycin also had significant reductions in the need for second endoscopy, volume of blood transfused, and length of hospital stay. Finally, there was a trend toward shorter endoscopic procedure times and decreased mortality for patients treated with erythromycin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    has also been compared with nasogastric lavage. A randomized trial with 253 patients that compared erythromycin alone with nasogastric lavage alone and nasogastric lavage plus erythromycin found that the quality of visualization did not differ significantly among the three groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, there were no differences among the groups with regard to procedure duration, rebleeding rates, need for second endoscopy, number of transfused units of blood, and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9942856\">",
"    <span class=\"h3\">",
"     Somatostatin and its analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin, or its analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , is used in the treatment of variceal bleeding and may also reduce the risk of bleeding due to nonvariceal causes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/41\">",
"     41",
"    </a>",
"    ]. In patients with suspected variceal bleeding, octreotide is given as an intravenous bolus of 20 to 50 mcg, followed by a continuous infusion at a rate of 25 to 50 mcg per hour. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of active variceal hemorrhage\", section on 'Somatostatin and its analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    is not recommended for routine use in patients with acute nonvariceal upper GI bleeding, but it can be used as adjunctive therapy in some cases. Its role is generally limited to settings in which endoscopy is unavailable or as a means to help stabilize patients before definitive therapy can be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H57224611#H57224611\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Somatostatin and octreotide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079763\">",
"    <span class=\"h3\">",
"     Antibiotics for patients with cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial infections are present in up to 20 percent of patients with cirrhosis who are hospitalized with gastrointestinal bleeding; up to an additional 50 percent develop an infection while hospitalized. Such patients have increased mortality.",
"   </p>",
"   <p>",
"    Multiple trials evaluating the effectiveness of prophylactic antibiotics in cirrhotic patients hospitalized for bleeding suggest an overall reduction in infectious complications and possibly decreased mortality. Antibiotics may also reduce the risk of recurrent bleeding in hospitalized patients who bled from esophageal varices. A reasonable conclusion from these data is that patients with cirrhosis who present with acute upper GI bleeding (from varices or other causes) should be given prophylactic antibiotics, preferably before endoscopy (although effectiveness has also been demonstrated when given after endoscopy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link&amp;anchor=H10#H10\">",
"     \"General principles of the management of variceal hemorrhage\", section on 'Infection and use of prophylactic antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H245946357\">",
"    <span class=\"h3\">",
"     Tranexamic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     Tranexamic acid",
"    </a>",
"    is an antifibrinolytic agent that has been studied in patients with upper GI bleeding. A meta-analysis that included seven randomized trials of tranexamic acid in patients with upper GI bleeding found a benefit with regard to mortality but not with regard to bleeding, surgery, or transfusion requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/42\">",
"     42",
"    </a>",
"    ]. When only studies that used antiulcer drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endoscopic therapy were included, there was no beneficial effect. This suggests that there is no role for tranexamic acid in the treatment of upper GI bleeding, since the current standard of care is to treat patients with proton pump inhibitors and endoscopic therapy (if indicated).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72879436\">",
"    <span class=\"h3\">",
"     Anticoagulants and antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;When possible, anticoagulants and antiplatelet agents should be held in patients with upper GI bleeding. However, the thrombotic risk of reversing anticoagulation should be weighed against the risk of continued bleeding without reversal, and thus the decision to discontinue medications or administer reversal agents needs to be individualized. In some cases (eg, stopping a nonsteroidal anti-inflammatory drug in a patient who is taking it for mild joint pain), the decision to stop these agents may be straightforward. However, in more complicated cases, consultation with the provider who prescribed the",
"    <span class=\"nowrap\">",
"     anticoagulant/antiplatelet",
"    </span>",
"    medication should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H1230806#H1230806\">",
"     \"Therapeutic use of warfarin\", section on 'Resumption of warfarin after bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\", section on 'Urgent procedures in anticoagulated patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H5#H5\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'High-risk conditions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\", section on 'Urgent procedures in patients on antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When to resume these medications once hemostasis has been achieved will also depend on the patient's risks for thrombosis and recurrent bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\", section on 'Resumption of anticoagulants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H97407782#H97407782\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Risk factors for persistent or recurrent bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079579\">",
"    <span class=\"h2\">",
"     Consultations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroenterological consultation should be obtained in all patients with suspected clinically significant acute upper GI bleeding. The decision to obtain surgical and interventional radiology consultations prior to endoscopy should be based upon the likelihood of persistent or recurrent bleeding, or",
"    <span class=\"nowrap\">",
"     risks/complications",
"    </span>",
"    stemming from endoscopic therapy (perforation, precipitation of massive bleeding).",
"   </p>",
"   <p>",
"    As a general rule, we obtain surgical consultation if endoscopic therapy is unlikely to be successful, if the patient is deemed to be at high risk for rebleeding or complications associated with endoscopy, or if there is concern that the patient may have an aorto-enteric fistula. In addition, a surgeon should be promptly notified of all patients with severe acute upper GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9942984\">",
"    <span class=\"h2\">",
"     Upper endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper endoscopy is the diagnostic modality of choice for acute upper GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Endoscopy has a high sensitivity and specificity for locating and identifying bleeding lesions in the upper GI tract. In addition, once a bleeding lesion has been identified, therapeutic endoscopy can achieve acute hemostasis and prevent recurrent bleeding in most patients. Early endoscopy (within 24 hours) is recommended for most patients with acute UGI bleeding, though whether early endoscopy affects outcomes and resource utilization is unsettled. (See",
"    <a class=\"local\" href=\"#H15597601\">",
"     'Early endoscopy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of active variceal hemorrhage\", section on 'Endoscopic treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Endoscopic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic findings in patients with peptic ulcers may be described using the Forrest classification [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/46\">",
"     46",
"    </a>",
"    ]. Findings include spurting hemorrhage (class Ia) (",
"    <a class=\"graphic graphic_picture graphicRef61646 \" href=\"UTD.htm?8/57/9119\">",
"     picture 1",
"    </a>",
"    ), oozing hemorrhage (class Ib), a nonbleeding visible vessel (class IIa) (",
"    <a class=\"graphic graphic_picture graphicRef54960 \" href=\"UTD.htm?33/44/34500\">",
"     picture 2",
"    </a>",
"    ), an adherent clot (class IIb) (",
"    <a class=\"graphic graphic_picture graphicRef76246 \" href=\"UTD.htm?10/24/10628\">",
"     picture 3",
"    </a>",
"    ), a flat pigmented spot (class IIc), and a clean ulcer base (class III). The endoscopic appearance helps determine which lesions require endoscopic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Endoscopic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Frequently, it is helpful to irrigate the stomach prior to endoscopy to help remove residual blood and other gastric contents. However, despite irrigation, the stomach can be obscured with blood, potentially making it difficult to establish a clear diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perform therapeutic maneuvers. In patients in whom bleeding stops spontaneously, a second-look endoscopy may be required to establish a diagnosis, but routine second-look endoscopy is not recommended. (See",
"    <a class=\"local\" href=\"#H5079470\">",
"     'Nasogastric lavage'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H6550756#H6550756\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Second-look endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Risks of endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risks of upper endoscopy include aspiration, adverse reactions to conscious sedation, perforation, and increasing bleeding while attempting therapeutic intervention. Patients need to be hemodynamically stable prior to undergoing endoscopy.",
"   </p>",
"   <p>",
"    However, while patients need to be hemodynamically stable, data suggest that most patients do not need to have a normal hematocrit in order to safely undergo endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, endoscopy appears to be safe in patients who are mildly to moderately anticoagulated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/23\">",
"     23",
"    </a>",
"    ]. In a retrospective study of 920 patients with upper GI bleeding undergoing upper endoscopy, patients with low hematocrits (&lt;30 percent) were similar to those with high hematocrits (&gt;30 percent) with regard to cardiovascular complications and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/47\">",
"     47",
"    </a>",
"    ]. In another retrospective study with 233 patients with upper GI bleeding who received endoscopic therapy, an elevated INR was not associated with an increased risk of rebleeding, transfusion requirement, surgery, length of stay, or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/23\">",
"     23",
"    </a>",
"    ]. The INR was between 1.3 and 2.7 in 95 percent of the patients, so the authors caution that the results of the study may only apply to patients who are mildly to moderately anticoagulated.",
"   </p>",
"   <p>",
"    The risks versus benefits of upper endoscopy should be considered in high-risk patients, such as those who have had a recent myocardial infarction. In one study, for example, 200 patients who underwent endoscopy within 30 days after myocardial infarction (MI) were compared with 200 controls matched for age, sex, and endoscopic indication [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/48\">",
"     48",
"    </a>",
"    ]. Complications (including fatal ventricular tachycardia, near respiratory arrest, and mild hypotension) occurred more often in patients who had a recent MI (8 versus 2 percent). Complications occurred more often (21 versus 2 percent) in patients who were very ill (Apache II score &gt;16 or hypotension prior to endoscopy). However, such patients are at increased risk for complications even without endoscopy and may be particularly vulnerable to complications from continued bleeding without endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=see_link\">",
"     \"Predictive scoring systems in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other diagnostic tests for acute upper GI bleeding include angiography and a tagged red blood cell scan, which can detect active bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Upper GI",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in the setting of acute upper GI bleeding because they will interfere with subsequent endoscopy, angiography, or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/44\">",
"     44",
"    </a>",
"    ]. There is also interest in using wireless capsule endoscopy for patients who have presented to the emergency department with suspected upper GI bleeding. An esophageal capsule (which has a recording time of 20 minutes) can be given in the emergency department and reviewed immediately for evidence of bleeding. Confirming the presence of blood in the stomach or duodenum may aid with patient triage and identify patients more likely to benefit from early endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A colonoscopy is generally required for patients with hematochezia and a negative upper endoscopy unless an alternative source for the bleeding has been identified. In addition, patients with melena and a negative upper endoscopy frequently undergo colonoscopy to rule out a right-sided colonic source for the bleeding, as such lesions may present with melena. In a study that included 1743 colonoscopies performed for the evaluation of melena following a non-diagnostic upper endoscopy, a suspected bleeding source was identified in 5 percent of patients, a rate that was higher than that seen in 194,979 average-risk screening controls (1 percent). Despite the relatively low yield in patients with melena, we routinely perform a colonoscopy in patients with melena and a negative upper endoscopy, as well as in patients with hematochezia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Colonoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic, clinical, and laboratory features may be useful for risk stratification of patients who present with acute upper GI bleeding (",
"    <a class=\"graphic graphic_table graphicRef78607 \" href=\"UTD.htm?22/10/22699\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52497 \" href=\"UTD.htm?40/62/41966\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/52-61\">",
"     52-61",
"    </a>",
"    ], and the use of risk stratification tools is recommended by the International Consensus Upper Gastrointestinal Bleeding Conference Group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/2\">",
"     2",
"    </a>",
"    ]. Factors associated with rebleeding identified in a meta-analysis included [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamic instability (systolic blood pressure less than 100 mmHg, heart rate greater than 100 beats per minute)",
"     </li>",
"     <li>",
"      Hemoglobin less than 10",
"      <span class=\"nowrap\">",
"       g/L",
"      </span>",
"     </li>",
"     <li>",
"      Active bleeding at the time of endoscopy",
"     </li>",
"     <li>",
"      Large ulcer size (greater than 1 to 3 cm in various studies)",
"     </li>",
"     <li>",
"      Ulcer location (posterior duodenal or high lesser gastric curvature)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several investigators have developed decision rules and predictive models that permit identification of patients who are at low risk for recurrent or life-threatening hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/63\">",
"     63",
"    </a>",
"    ]. Such patients may be suitable for early hospital discharge or even outpatient care. The effectiveness of such rules has been evaluated in a variety of clinical settings, with most studies suggesting that patients deemed to be low-risk can safely be discharged early or treated as outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/52-58,63-71\">",
"     52-58,63-71",
"    </a>",
"    ]. In addition, this approach is associated with reduced resource utilization compared with universal hospitalization of patients with acute upper GI bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15597594\">",
"    <span class=\"h2\">",
"     Risk scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two commonly cited scoring systems are the Rockall score and the Blatchford score:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Rockall score is based upon age, the presence of shock, comorbidity, diagnosis, and endoscopic stigmata of recent hemorrhage (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?27/11/27838?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/52\">",
"       52",
"      </a>",
"      ]. In one validation study, only 32 of 744 patients (4 percent) who scored 2 or less (out of a maximum of 11) rebled and only one died.",
"      <br/>",
"      <br/>",
"      On the other hand, in a later study of 247 patients who underwent endoscopic therapy for bleeding peptic ulcers, the model performed poorly when predicting recurrent bleeding, underscoring the need for validation of these models [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Blatchford score (also known as the Glasgow Blatchford score), unlike the Rockall score, does not take endoscopic data into account and thus can be used when the patient first presents (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?18/56/19329?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/57\">",
"       57",
"      </a>",
"      ]. The score is based upon the blood urea nitrogen, hemoglobin, systolic blood pressure, pulse, and the presence of melena, syncope, hepatic disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac failure. The score ranges from zero to 23 and the risk of requiring endoscopic intervention increases with increasing score. One meta-analysis found that a Blatchford score of zero was associated with a low likelihood of the need for urgent endoscopic intervention (likelihood ratio 0.02, 95% confidence interval [CI] 0-0.05) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A simpler version of the score, known as the modified Glasgow Blatchford score, is calculated using only the blood urea nitrogen, hemoglobin, systolic blood pressure, and pulse. The score ranges from 0 to 16. A prospective study of the modified score found that it performed as well as the full Blatchford score and that it outperformed the Rockall score with regard to predicting the need for clinical intervention, rebleeding, and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AIMS65 is another scoring system that uses data available prior to endoscopy. Studies suggest it has high accuracy for predicting inpatient mortality among patients with upper GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/61,74\">",
"     61,74",
"    </a>",
"    ]. The score was derived using data from a database that contained information from 187 United States hospitals. The derivation cohort used data from 29,222 hospital admissions. The score was then validated using a separate data set containing information from 32,504 admissions. The study found that five factors were associated with increased inpatient mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       A",
"      </strong>",
"      lbumin less than 3.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       I",
"      </strong>",
"      NR greater than 1.5",
"     </li>",
"     <li>",
"      Altered",
"      <strong>",
"       M",
"      </strong>",
"      ental status (Glasgow coma score less than 14, disorientation, lethargy, stupor, or coma)",
"     </li>",
"     <li>",
"      <strong>",
"       S",
"      </strong>",
"      ystolic blood pressure of 90 mmHg or less",
"     </li>",
"     <li>",
"      Age older than",
"      <strong>",
"       65",
"      </strong>",
"      years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the validation cohort, the mortality rate increased significantly as the number of risk factors present increased:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Zero risk factors: 0.3 percent",
"     </li>",
"     <li>",
"      One risk factor: 1 percent",
"     </li>",
"     <li>",
"      Two risk factors: 3 percent",
"     </li>",
"     <li>",
"      Three risk factors: 9 percent",
"     </li>",
"     <li>",
"      Four risk factors: 15 percent",
"     </li>",
"     <li>",
"      Five risk factors: 25 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to predicting mortality, an increasing score was also associated with increased length of stay (from 3.4 days for zero risk factors to 8.1 days for five risk factors) and increased cost (average cost of $5647 USD with zero risk factors to $15,776 USD with five risk factors). Prospective studies are needed to confirm the ability of the score to predict mortality, length of stay, and cost. In addition, it is not yet known if the score predicts rebleeding following endoscopic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15597601\">",
"    <span class=\"h2\">",
"     Early endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have reached variable conclusions when determining whether the application of early endoscopy for risk stratification and treatment reduces resource utilization or affects patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/66,75-78\">",
"     66,75-78",
"    </a>",
"    ]. Whereas some studies have demonstrated reduced resource utilization and improved outcomes from early endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/77,78\">",
"     77,78",
"    </a>",
"    ], other studies, including a randomized trial, did not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/66,75\">",
"     66,75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the randomized trial, 93 outpatients with acute upper GI bleeding were assigned to urgent endoscopy (before hospitalization) or elective endoscopy after admission [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/66\">",
"       66",
"      </a>",
"      ]. Results of the urgent endoscopy and a recommendation regarding patient disposition were provided to the attending clinician who made the final decision regarding patient disposition.",
"      <br/>",
"      <br/>",
"      The timing of endoscopy did not affect resource utilization or patient outcomes. Length of stay was similar (4 versus 5 days in the urgent and delayed groups, respectively), as was the mean number of days in the intensive care unit (1.2). Outpatient care was recommended for 19 patients (40 percent) in the urgent endoscopy group. However, the attending clinicians who were responsible for making the discharge decisions only followed the recommendation for outpatient care in four patients.",
"      <br/>",
"      <br/>",
"      This trial suggests that in order for early endoscopy to reduce resource utilization, stratification needs to translate into changes in patient management. Studies showing reduced utilization have incorporated processes by which patient disposition was linked directly to the risk stratification system.",
"     </li>",
"     <li>",
"      A benefit for early endoscopy (defined as endoscopy within one day of admission) was suggested by a large retrospective study using a database of hospital inpatient admissions (Nationwide Inpatient Sample) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/78\">",
"       78",
"      </a>",
"      ]. The study looked at 35,747 adults with acute variceal bleeding and 435,765 adults with nonvariceal upper GI bleeding. Among patients with acute variceal hemorrhage, inpatient mortality was 8.3 percent for those who underwent upper endoscopy within one day of admission and was 15.3 percent for those who did not (adjusted odds ratio [OR] 1.18; 95% CI 1.08-1.31). For patients with nonvariceal upper GI bleeding, the corresponding mortality rates were 2.5 and 6.6 percent, respectively (adjusted OR 1.32; 95% CI 1.26-1.38).",
"      <br/>",
"      <br/>",
"      However, a limitation of the study is that it did not differentiate patients who were admitted with upper GI bleeding from those who developed upper GI bleeding while hospitalized for other reasons (most of whom would presumably undergo endoscopy more than one day following hospital admission). This could skew the results toward increased mortality in the patients who did not undergo early endoscopy since patients who develop bleeding as inpatients are known to have higher mortality rates [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study that suggested a benefit with regard to mortality included 8222 patients with upper GI bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/77\">",
"       77",
"      </a>",
"      ]. Patients who died had a significantly longer waiting time to endoscopy than those who survived (1.65 versus 0.95 days; adjusted OR 1.10, 95% CI 1.06-1.14).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15597608\">",
"    <span class=\"h2\">",
"     Implementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data presented above suggest that risk stratification is feasible and permits identification of patients who can be managed safely without hospitalization. However, for these systems to be successful, the risk stratification system must be tied directly to decisions regarding patient discharge. None of the published risk scores has yet been adopted widely.",
"   </p>",
"   <p>",
"    We do not routinely use any of the scoring systems of risk stratification. As a general rule, we discharge patients who meet the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have no comorbidities",
"     </li>",
"     <li>",
"      Have a negative NGT aspiration",
"     </li>",
"     <li>",
"      Have stable vital signs",
"     </li>",
"     <li>",
"      Have a normal hemoglobin",
"     </li>",
"     <li>",
"      Have a likely bleeding source identified on upper endoscopy",
"     </li>",
"     <li>",
"      Have a source of bleeding that is not associated with a high risk of rebleeding (eg, variceal bleeding, active bleeding, bleeding from a Dieulafoy's lesion, or ulcer bleeding with high-risk stigmata) (",
"      <a class=\"graphic graphic_table graphicRef78607 \" href=\"UTD.htm?22/10/22699\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the decision to discharge a patient also depends upon individual-patient factors, such as reliability for follow-up and confidence in the diagnosis; in some cases, we admit patients who appear to be low-risk for observation.",
"   </p>",
"   <p>",
"    If patients do not meet these criteria we admit them to a monitored setting or intensive care unit (depending upon the severity of bleeding, comorbidities, and stability of vital signs). Most patients who have received endoscopic treatment for high-risk stigmata should be hospitalized for 72 hours to monitor for rebleeding, since most rebleeding occurs during this time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/55/28538/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with upper GI bleeding due to various causes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15528?source=see_link\">",
"     \"Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24515?source=see_link\">",
"       \"Patient information: GI bleed (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A table outlining the emergency management of acute severe upper gastrointestinal bleeding is provided (",
"      <a class=\"graphic graphic_table graphicRef72195 \" href=\"UTD.htm?19/12/19661\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful history should be obtained to identify potential sources of the upper GI bleed, assess the severity of the bleed, and to identify comorbid conditions that may influence the patient's subsequent management. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination should focus on signs that indicate the severity of blood loss, help localize the source of the bleeding, and suggest complications. (See",
"      <a class=\"local\" href=\"#H684000\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of abdominal pain, especially if severe and associated with rebound tenderness or involuntary guarding raises concern for perforation. If any signs of an acute abdomen are present, further evaluation to exclude a perforation is required prior to endoscopy. (See",
"      <a class=\"local\" href=\"#H684000\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory tests obtained in patients with acute upper gastrointestinal bleeding include a complete blood count, serum chemistries, liver tests, and coagulation studies. In addition, we suggest ruling out a myocardial infarction in elderly patients and those with known cardiovascular disease who have severe bleeding, especially if there has been hemodynamic instability. (See",
"      <a class=\"local\" href=\"#H5079205\">",
"       'Laboratory data'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients only undergo NGT lavage if particulate matter, fresh blood, and clots need to be removed from the stomach to facilitate endoscopy. (See",
"      <a class=\"local\" href=\"#H5079470\">",
"       'Nasogastric lavage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who require hospitalization should be admitted to a monitored bed or intensive care unit depending upon the severity of bleeding. (See",
"      <a class=\"local\" href=\"#H5079565\">",
"       'Triage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General supportive measures include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Provision of supplemental oxygen by nasal cannula",
"     </li>",
"     <li>",
"      Nothing per mouth",
"     </li>",
"     <li>",
"      Two large caliber (16 gauge or larger) peripheral catheters or a central venous line",
"     </li>",
"     <li>",
"      Placement of a pulmonary artery catheter should be considered in patients with hemodynamic instability or who need close monitoring during resuscitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the majority of patients with acute upper gastrointestinal bleeding who do not have significant comorbid illnesses, we recommend giving blood transfusions to maintain the hemoglobin at &ge;7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      rather than &ge;9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. For patients at increased risk of suffering adverse events in the setting of significant anemia, such as those with unstable coronary artery disease, we suggest transfusing to maintain the hemoglobin at &ge;9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      rather than &ge;7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5079586\">",
"       'Blood transfusions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Blood transfusion'",
"      </a>",
"      .).",
"      <br/>",
"      <br/>",
"      In patients with suspected variceal bleeding, we suggest transfusing to a hemoglobin of no more than 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It is particularly important to avoid overtransfusion in patients with suspected variceal bleeding, as it can precipitate worsening of the bleeding. (See",
"      <a class=\"local\" href=\"#H5079586\">",
"       'Blood transfusions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with acute upper GI bleeding be treated with an intravenous PPI at presentation until confirmation of the cause of bleeding, after which the need for specific therapy and the duration of PPI use can be determined (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5079756\">",
"       'Acid suppression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H57224540#H57224540\">",
"       \"Overview of the treatment of bleeding peptic ulcers\", section on 'Acid suppression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      be given prior to endoscopy in patients who are likely to have a large amount of blood in their stomach, such as those with severe bleeding. A reasonable dose is 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously over 20 to 30 minutes, 30 to 90 minutes prior to endoscopy. (See",
"      <a class=\"local\" href=\"#H5079922\">",
"       'Prokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients known to have cirrhosis who present with acute upper GI bleeding receive antibiotics, preferably before endoscopy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link&amp;anchor=H10#H10\">",
"       \"General principles of the management of variceal hemorrhage\", section on 'Infection and use of prophylactic antibiotics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend upper endoscopy for the evaluation and management of clinically significant (ie, more than a scant amount of blood) acute upper GI bleeding (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Additional diagnostic tests may be required in specific circumstances. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of patients with upper GI bleeding due to various causes is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"       \"Overview of the treatment of bleeding peptic ulcers\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15528?source=see_link\">",
"       \"Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link\">",
"       \"Treatment of active variceal hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/1\">",
"      Barkun A, Bardou M, Marshall JK, Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003; 139:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/2\">",
"      Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/3\">",
"      Hwang JH, Fisher DA, Ben-Menachem T, et al. The role of endoscopy in the management of acute non-variceal upper GI bleeding. Gastrointest Endosc 2012; 75:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/4\">",
"      Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012; 107:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/5\">",
"      Srygley FD, Gerardo CJ, Tran T, Fisher DA. Does this patient have a severe upper gastrointestinal bleed? JAMA 2012; 307:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/6\">",
"      Cappell MS, Friedel D. Initial management of acute upper gastrointestinal bleeding: from initial evaluation up to gastrointestinal endoscopy. Med Clin North Am 2008; 92:491.",
"     </a>",
"    </li>",
"    <li>",
"     Current diagnosis and treatment: Surgery, 13, Doherty G (Ed), McGraw-Hill Companies, 2010. p.493.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/8\">",
"      Jensen DM, Machicado GA. Diagnosis and treatment of severe hematochezia. The role of urgent colonoscopy after purge. Gastroenterology 1988; 95:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/9\">",
"      Palmer ED. The vigorous diagnostic approach to upper-gastrointestinal tract hemorrhage. A 23-year prospective study of 1,4000 patients. JAMA 1969; 207:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/10\">",
"      Richards RJ, Donica MB, Grayer D. Can the blood urea nitrogen/creatinine ratio distinguish upper from lower gastrointestinal bleeding? J Clin Gastroenterol 1990; 12:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/11\">",
"      Mortensen PB, N&oslash;hr M, M&oslash;ller-Petersen JF, Balslev I. The diagnostic value of serum urea/creatinine ratio in distinguishing between upper and lower gastrointestinal bleeding. A prospective study. Dan Med Bull 1994; 41:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/12\">",
"      Pallin DJ, Saltzman JR. Is nasogastric tube lavage in patients with acute upper GI bleeding indicated or antiquated? Gastrointest Endosc 2011; 74:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/13\">",
"      Huang ES, Karsan S, Kanwal F, et al. Impact of nasogastric lavage on outcomes in acute GI bleeding. Gastrointest Endosc 2011; 74:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/14\">",
"      Aljebreen AM, Fallone CA, Barkun AN. Nasogastric aspirate predicts high-risk endoscopic lesions in patients with acute upper-GI bleeding. Gastrointest Endosc 2004; 59:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/15\">",
"      Baradarian R, Ramdhaney S, Chapalamadugu R, et al. Early intensive resuscitation of patients with upper gastrointestinal bleeding decreases mortality. Am J Gastroenterol 2004; 99:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/16\">",
"      Duggan JM. Gastrointestinal hemorrhage: should we transfuse less? Dig Dis Sci 2009; 54:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/17\">",
"      Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/18\">",
"      Kravetz D, Bosch J, Arderiu M, et al. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting. Hepatology 1989; 9:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/19\">",
"      Cerqueira RM, Andrade L, Correia MR, et al. Risk factors for in-hospital mortality in cirrhotic patients with oesophageal variceal bleeding. Eur J Gastroenterol Hepatol 2012; 24:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/20\">",
"      Krige JE, Kotze UK, Distiller G, et al. Predictive factors for rebleeding and death in alcoholic cirrhotic patients with acute variceal bleeding: a multivariate analysis. World J Surg 2009; 33:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/21\">",
"      McCormick PA, Jenkins SA, McIntyre N, Burroughs AK. Why portal hypertensive varices bleed and bleed: a hypothesis. Gut 1995; 36:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/22\">",
"      Restellini S, Kherad O, Jairath V, et al. Red blood cell transfusion is associated with increased rebleeding in patients with nonvariceal upper gastrointestinal bleeding. Aliment Pharmacol Ther 2013; 37:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/23\">",
"      Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol 2007; 102:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/24\">",
"      Maltz GS, Siegel JE, Carson JL. Hematologic management of gastrointestinal bleeding. Gastroenterol Clin North Am 2000; 29:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/25\">",
"      ASGE Standards of Practice Committee, Anderson MA, Ben-Menachem T, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/26\">",
"      Dorward S, Sreedharan A, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2006; :CD005415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/27\">",
"      Gisbert JP, Gonz&aacute;lez L, Calvet X, et al. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001; 15:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/28\">",
"      Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003; 17:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/29\">",
"      Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/30\">",
"      Chan WH, Khin LW, Chung YF, et al. Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding. Br J Surg 2011; 98:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/31\">",
"      Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/32\">",
"      Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007; 356:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/33\">",
"      Al-Sabah S, Barkun AN, Herba K, et al. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2008; 6:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/34\">",
"      Frossard JL, Spahr L, Queneau PE, et al. Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Gastroenterology 2002; 123:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/35\">",
"      Coffin B, Pocard M, Panis Y, et al. Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. Gastrointest Endosc 2002; 56:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/36\">",
"      Altraif I, Handoo FA, Aljumah A, et al. Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial. Gastrointest Endosc 2011; 73:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/37\">",
"      Carbonell N, Pauwels A, Serfaty L, et al. Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am J Gastroenterol 2006; 101:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/38\">",
"      Barkun AN, Bardou M, Martel M, et al. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc 2010; 72:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/39\">",
"      Bai Y, Guo JF, Li ZS. Meta-analysis: erythromycin before endoscopy for acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2011; 34:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/40\">",
"      Pateron D, Vicaut E, Debuc E, et al. Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med 2011; 57:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/41\">",
"      Imperiale TF, Birgisson S. Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Ann Intern Med 1997; 127:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/42\">",
"      Gluud LL, Klingenberg SL, Langholz E. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2012; 1:CD006640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/43\">",
"      Kolkman JJ, Meuwissen SG. A review on treatment of bleeding peptic ulcer: a collaborative task of gastroenterologist and surgeon. Scand J Gastroenterol Suppl 1996; 218:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/44\">",
"      Jutabha R, Jensen DM. Management of upper gastrointestinal bleeding in the patient with chronic liver disease. Med Clin North Am 1996; 80:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/45\">",
"      Adang RP, Vismans JF, Talmon JL, et al. Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. Gastrointest Endosc 1995; 42:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/46\">",
"      Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974; 2:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/47\">",
"      Balderas V, Bhore R, Lara LF, et al. The hematocrit level in upper gastrointestinal hemorrhage: safety of endoscopy and outcomes. Am J Med 2011; 124:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/48\">",
"      Cappell MS, Iacovone FM Jr. Safety and efficacy of esophagogastroduodenoscopy after myocardial infarction. Am J Med 1999; 106:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/49\">",
"      Barth KH. Radiological intervention in upper and lower gastrointestinal bleeding. Baillieres Clin Gastroenterol 1995; 9:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/50\">",
"      Emslie JT, Zarnegar K, Siegel ME, Beart RW Jr. Technetium-99m-labeled red blood cell scans in the investigation of gastrointestinal bleeding. Dis Colon Rectum 1996; 39:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/51\">",
"      Gralnek IM, Ching JY, Maza I, et al. Capsule endoscopy in acute upper gastrointestinal hemorrhage: a prospective cohort study. Endoscopy 2013; 45:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/52\">",
"      Rockall TA, Logan RF, Devlin HB, Northfield TC. Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 1996; 347:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/53\">",
"      Corley DA, Stefan AM, Wolf M, et al. Early indicators of prognosis in upper gastrointestinal hemorrhage. Am J Gastroenterol 1998; 93:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/54\">",
"      Stanley AJ, Robinson I, Forrest EH, et al. Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis. QJM 1998; 91:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/55\">",
"      Hay JA, Maldonado L, Weingarten SR, Ellrodt AG. Prospective evaluation of a clinical guideline recommending hospital length of stay in upper gastrointestinal tract hemorrhage. JAMA 1997; 278:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/56\">",
"      Hay JA, Lyubashevsky E, Elashoff J, et al. Upper gastrointestinal hemorrhage clinical--guideline determining the optimal hospital length of stay. Am J Med 1996; 100:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/57\">",
"      Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000; 356:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/58\">",
"      Cipolletta L, Bianco MA, Rotondano G, et al. Outpatient management for low-risk nonvariceal upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 2002; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/59\">",
"      Marmo R, Koch M, Cipolletta L, et al. Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED Score and Prospective Comparison with the Rockall Score. Am J Gastroenterol 2010; 105:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/60\">",
"      Pang SH, Ching JY, Lau JY, et al. Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endoscopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc 2010; 71:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/61\">",
"      Saltzman JR, Tabak YP, Hyett BH, et al. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc 2011; 74:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/62\">",
"      Garc&iacute;a-Iglesias P, Villoria A, Suarez D, et al. Meta-analysis: predictors of rebleeding after endoscopic treatment for bleeding peptic ulcer. Aliment Pharmacol Ther 2011; 34:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/63\">",
"      Das A, Wong RC. Prediction of outcome of acute GI hemorrhage: a review of risk scores and predictive models. Gastrointest Endosc 2004; 60:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/64\">",
"      Brullet E, Campo R, Calvet X, et al. A randomized study of the safety of outpatient care for patients with bleeding peptic ulcer treated by endoscopic injection. Gastrointest Endosc 2004; 60:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/65\">",
"      Gralnek IM, Dulai GS. Incremental value of upper endoscopy for triage of patients with acute non-variceal upper-GI hemorrhage. Gastrointest Endosc 2004; 60:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/66\">",
"      Bjorkman DJ, Zaman A, Fennerty MB, et al. Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effectiveness study. Gastrointest Endosc 2004; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/67\">",
"      Longstreth GF, Feitelberg SP. Successful outpatient management of acute upper gastrointestinal hemorrhage: use of practice guidelines in a large patient series. Gastrointest Endosc 1998; 47:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/68\">",
"      Lee JG, Turnipseed S, Romano PS, et al. Endoscopy-based triage significantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999; 50:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/69\">",
"      Imperiale TF, Dominitz JA, Provenzale DT, et al. Predicting poor outcome from acute upper gastrointestinal hemorrhage. Arch Intern Med 2007; 167:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/70\">",
"      Das A, Ben-Menachem T, Farooq FT, et al. Artificial neural network as a predictive instrument in patients with acute nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 2008; 134:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/71\">",
"      Stanley AJ, Ashley D, Dalton HR, et al. Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet 2009; 373:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/72\">",
"      Church NI, Dallal HJ, Masson J, et al. Validity of the Rockall scoring system after endoscopic therapy for bleeding peptic ulcer: a prospective cohort study. Gastrointest Endosc 2006; 63:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/73\">",
"      Cheng DW, Lu YW, Teller T, et al. A modified Glasgow Blatchford Score improves risk stratification in upper gastrointestinal bleed: a prospective comparison of scoring systems. Aliment Pharmacol Ther 2012; 36:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/74\">",
"      Hyett BH, Abougergi MS, Charpentier JP, et al. The AIMS65 score compared with the Glasgow-Blatchford score in predicting outcomes in upper GI bleeding. Gastrointest Endosc 2013; 77:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/75\">",
"      Sarin N, Monga N, Adams PC. Time to endoscopy and outcomes in upper gastrointestinal bleeding. Can J Gastroenterol 2009; 23:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/76\">",
"      Tsoi KK, Ma TK, Sung JJ. Endoscopy for upper gastrointestinal bleeding: how urgent is it? Nat Rev Gastroenterol Hepatol 2009; 6:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/77\">",
"      Tsoi KK, Chiu PW, Chan FK, et al. The risk of peptic ulcer bleeding mortality in relation to hospital admission on holidays: a cohort study on 8,222 cases of peptic ulcer bleeding. Am J Gastroenterol 2012; 107:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/78\">",
"      Wysocki JD, Srivastav S, Winstead NS. A nationwide analysis of risk factors for mortality and time to endoscopy in upper gastrointestinal haemorrhage. Aliment Pharmacol Ther 2012; 36:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/55/28538/abstract/79\">",
"      Hearnshaw SA, Logan RF, Lowe D, et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60:1327.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2548 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28538=[""].join("\n");
var outline_f27_55_28538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H683979\">",
"      Bleeding manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H684310\">",
"      Past medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H684391\">",
"      Medication history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H683993\">",
"      Symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H684000\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5079205\">",
"      Laboratory data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5079470\">",
"      Nasogastric lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5079565\">",
"      Triage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5079990\">",
"      General support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5079572\">",
"      Fluid resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5079586\">",
"      Blood transfusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5079594\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5079756\">",
"      - Acid suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5079922\">",
"      - Prokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9942856\">",
"      - Somatostatin and its analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5079763\">",
"      - Antibiotics for patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H245946357\">",
"      - Tranexamic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72879436\">",
"      - Anticoagulants and antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5079579\">",
"      Consultations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9942984\">",
"      Upper endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Risks of endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15597594\">",
"      Risk scores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15597601\">",
"      Early endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15597608\">",
"      Implementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2548\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2548|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/57/9119\" title=\"picture 1\">",
"      Actively bleeding GU Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/44/34500\" title=\"picture 2\">",
"      Duodenal ulcer with visible vessel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/24/10628\" title=\"picture 3\">",
"      Gastric ulcer with adherent clot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/62/41966\" title=\"picture 4\">",
"      Ulcers with low rebleeding risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2548|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/12/19661\" title=\"table 1\">",
"      Rapid overview emergency management severe upper GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/10/22699\" title=\"table 2\">",
"      Predictors repeat ulcer bleed",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/11/27838?source=related_link\" title=\"calculator 1\">",
"      Calculator: Rockall score for upper gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?18/56/19329?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blatchford score for gastrointestinal bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=related_link\">",
"      Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15528?source=related_link\">",
"      Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=related_link\">",
"      Evaluation of obscure gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=related_link\">",
"      General principles of the management of variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12664?source=related_link\">",
"      Major causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=related_link\">",
"      Medication-induced esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=related_link\">",
"      Nasogastric and nasoenteric tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24515?source=related_link\">",
"      Patient information: GI bleed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=related_link\">",
"      Uncommon causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_55_28539="Obesity and ICU trials";
var content_f27_55_28539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evidence-based medicine and the critically ill bariatric patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Subject",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight exclusion criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early goal-directed thrapy in patients with sepsis",
"       </td>",
"       <td>",
"        Rivers, 2001",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low tidal volumes in ARDS",
"       </td>",
"       <td>",
"        ARDSnet, 2000",
"       </td>",
"       <td>",
"        Excluded if weight &gt;1 kg/cm of height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low-dose corticosteroids for refractory shock",
"       </td>",
"       <td>",
"        Annane, 2002",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intensive insulin therapy",
"       </td>",
"       <td>",
"        van den Berghe, 2001",
"       </td>",
"       <td>",
"        N/A; mean body mass index = 26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daily dialysis in renal failure",
"       </td>",
"       <td>",
"        Schiffl, 2002",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Effect of PA catheter",
"       </td>",
"       <td>",
"        Sandham, 2003",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Richard, 2003",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N/A: not available; ARDS: acute respiratory distress syndrome; PA: pulmonary artery.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28539=[""].join("\n");
var outline_f27_55_28539=null;
var title_f27_55_28540="Turner estrogen dose";
var content_f27_55_28540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ovarian hormone replacement treatment in Turner syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age, yr",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age-specific suggestions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-11",
"       </td>",
"       <td>",
"        Monitor for spontaneous puberty by Tanner staging and FSH level",
"       </td>",
"       <td>",
"        Low-dose estrogen treatment may not inhibit GH-enhanced growth in stature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12-13",
"       </td>",
"       <td>",
"        If no spontaneous development and FSH elevated, begin low dose E2",
"       </td>",
"       <td>",
"        Equivalent initial E2 doses: depot (im) E2, 0.2-0.4 mg/month; transdermal E2, 6.25 &micro;g daily*; micronized E2, 0.25 mg daily by mouth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12.5-15",
"       </td>",
"       <td>",
"        Gradually increase E2 dose over about 2 yr (eg, 14, 25, 37, 50, 75, 100, 200 &micro;g daily via patch) to adult dose",
"       </td>",
"       <td>",
"        Usual adult daily dose is 100-200 &micro;g transdermal E2, 2-4 mg micronized E2, 20 &micro;g EE2, 1.25-2.5 mg CEE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14-16",
"       </td>",
"       <td>",
"        Begin cyclic progesterone treatment after 2 yr of estrogen or when breakthrough bleeding occurs",
"       </td>",
"       <td>",
"        Oral micronized progesterone best option at present; usual adult dose is 200 mg/d on d 20-30 of monthly cycle or d 100-120 of 3-month cycle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14-30",
"       </td>",
"       <td>",
"        Continue full doses at least until age 30 because normally estrogen levels are highest between age 15 and 30 yr",
"       </td>",
"       <td>",
"        Some women may prefer using oral or transdermal contraceptive for HRT; monitor endometrial thickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-50",
"       </td>",
"       <td>",
"        The lowest estrogen dose providing full protection",
"        <em>",
"         vs.",
"        </em>",
"        osteoporosis is 0.625 CEE or equivalent",
"       </td>",
"       <td>",
"        Monitor osteoporosis risk factors, diet, exercise; obtain BMD and begin regular screening mammography by age 45 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;50",
"       </td>",
"       <td>",
"        Decision on estrogen use based on same considerations as for other postmenopausal women",
"       </td>",
"       <td>",
"        New HRT options are appearing, and these recommendations may need updating in near future",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CEE: conjugated equine estrogens; E2: estradiol; EE2: ethinyl estradiol; HRT: hormone replacement treatment.",
"     <br>",
"      * The lowest-dose commercially available E2 transdermal patches deliver 14 and 25 &micro;g daily; it is not established whether various means of dose fractionation (eg, administering a quarter patch overnight or daily or administering whole patches for 7-10 d per month) are equivalent.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner Syndrome: A guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007; 92:8. Copyright &copy; 2007 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28540=[""].join("\n");
var outline_f27_55_28540=null;
var title_f27_55_28541="Classification of jaundice";
var content_f27_55_28541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of jaundice according to type of bile pigment and mechanism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Unconjugated hyperbilirubinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Increased bilirubin production*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Extravascular hemolysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Extravasation of blood into tissues",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intravascular hemolysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dyserythropoiesis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Impaired hepatic bilirubin uptake",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Portosystemic shunts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Some patients with Gilbert's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Certain drugs",
"            <sup>",
"             &bull;",
"            </sup>",
"            - rifampin, probenecid, flavaspadic acid, bunamiodyl",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Impaired bilirubin conjugation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Crigler-Najjar syndrome types I and II",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gilbert's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neonates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hyperthyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ethinyl estradiol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Liver diseases - chronic hepatitis, advanced cirrhosis, Wilson disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Conjugated hyperbilirubinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Extrahepatic cholestasis (biliary obstruction)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Choledocholithiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intrinsic and extrinsic tumors - eg, cholangiocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Primary sclerosing cholangitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            AIDS cholangiopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acute and chronic pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Strictures after invasive procedures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Certain parasitic infections - eg,",
"            <em>",
"             Ascaris lumbricoides",
"            </em>",
"            , liver flukes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Intrahepatic cholestasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Viral hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Alcoholic hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nonalcoholic steatohepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Primary biliary cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Drugs and toxins - eg, alkylated steroids, chlorpromazine, herbal medications (eg, Jamaican bush tea), arsenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sepsis and hypoperfusion states",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infiltrative diseases - eg, amyloidosis, lymphoma, sarcoidosis, tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Total parenteral nutrition",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Postoperative cholestasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Following organ transplantation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hepatic crisis in sickle cell disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            End-stage liver disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AIDS: acquired immunodeficiency syndrome.",
"     <br/>",
"     * Serum bilirubin concentration usually less than 4 mg/dL (68 mmol/L) in the absence of underlying liver disease.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The hyperbilirubinemia induced by drugs usually resolves within 48 hours after the drug is discontinued.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28541=[""].join("\n");
var outline_f27_55_28541=null;
var title_f27_55_28542="Hyperextension exercise for back pain";
var content_f27_55_28542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Hyperextension exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient should lie face down on the floor or on a firm bed with a pillow under the abdomen and hips. The arms should be resting at the sides. The chin should be held in or neutral. The patient should inhale and raise the head, neck, chest (as a block), and arms a few inches from the floor. Hold for five seconds. Repeat five to ten times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28542=[""].join("\n");
var outline_f27_55_28542=null;
var title_f27_55_28543="Cervical agenesis A";
var content_f27_55_28543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical agenesis with the presence of a vagina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_55_28543=[""].join("\n");
var outline_f27_55_28543=null;
           